<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:ncit="http://purl.bioontology.org/ontology/NCIT#"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:poc="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2F60DE8-DB29-4E1E-870B-8EBBD05CD648">
    <pav:createdOn>2014-06-02 11:23:15 -0400</pav:createdOn>
    <ao:suffix> Aminoglutethimide reduces tamoxifen and N-desmethyl tamoxifen plasma concentrations. Medroxyprogesterone reduces plasma concentrations of N-desmethyl, but not tamoxifen</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D2F60DE8-DB29-4E1E-870B-8EBBD05CD648"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Tamoxifen reduced the plasma concentration of letrozole by 37% when these drugs were coadministered. Rifampin, a cytochrome P-450 3A4 inducer reduced tamoxifen AUC and Cmax by 86% and 55%, respectively.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid>D2F60DE8-DB29-4E1E-870B-8EBBD05CD648</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1E5BCF5-10F0-4E64-9946-E346FE9491EB">
    <sio:SIO_000111>(34068-7) DOSAGE AND ADMINISTRATION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34068-7) DOSAGE AND ADMINISTRATION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:802288B4-922E-4898-A87B-459F64B69564">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:802288B4-922E-4898-A87B-459F64B69564"/>
    <ao:suffix>. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapyÂ </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <pav:createdOn>2014-06-01 18:56:26 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F9F5F59-7754-4F91-9B42-F5BE5C8ADAD8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F9F5F59-7754-4F91-9B42-F5BE5C8ADAD8"/>
    <domeo:uuid>7F9F5F59-7754-4F91-9B42-F5BE5C8ADAD8</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-06-11 13:35:02 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA8988F3-1346-4B78-A914-D18381CEF56A">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA9237D5-68E7-4218-9215-072A32A7DD0C">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>DPYD</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3012</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D27F296F-4104-4FB6-910F-4B5BD4D67EA1">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:106ABB0B-6E1C-4AF2-9606-A390F46EBE96">
    <ao:exact> Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.</ao:exact>
    <ao:suffix> For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele</ao:suffix>
    <pav:createdOn>2014-06-11 13:34:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>ents (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>106ABB0B-6E1C-4AF2-9606-A390F46EBE96</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:106ABB0B-6E1C-4AF2-9606-A390F46EBE96"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:085DCEC8-3AA0-4DF0-8132-C06E95CFC077">
    <ao:body rdf:resource="urn:linkedspls:uuid:F3A1AA6C-1963-4703-920E-3BA4EA5D0089"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:731E542F-F12E-49C7-891D-55159666E4E6"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C5288E1E-A5A7-443D-9D68-3557A9B8EC13"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:7E624625-74D5-411B-97D7-418C14CF1E5F</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:7841625B-9726-42EA-AA7C-920793ED16BB"/>
    <pav:lastSavedOn>2014-06-11 13:32:06 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:A5BFB7BD-0889-46E3-8363-DF3748E897E4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2041E76D-52F2-403B-AC36-D990EF008C61"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6D861CA-F528-4F4C-9D8C-092E0C266BCA"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <pav:createdOn>2014-06-11 13:32:05 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:022EF4DB-AF0D-45EF-8063-1DF9D5727347">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:022EF4DB-AF0D-45EF-8063-1DF9D5727347"/>
    <pav:createdOn>2014-08-02 11:36:49 -0400</pav:createdOn>
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/VORICONAZOLE-ce3ef5cf-3087-4d92-9d94-9eb8287228db.html</ao:hasSource>
    <ao:exact>Subjects who are heterozygous extensive metabolizers have, on average, 2-fold higher voriconazole exposure than their homozygous extensive metabolizer counterparts</ao:exact>
    <domeo:uuid>022EF4DB-AF0D-45EF-8063-1DF9D5727347</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C44D8A99-C64C-4B6C-A7B2-838CCA24F46A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C44D8A99-C64C-4B6C-A7B2-838CCA24F46A"/>
    <domeo:uuid>C44D8A99-C64C-4B6C-A7B2-838CCA24F46A</domeo:uuid>
    <ao:suffix> The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug (AED) dose, compliance, concomitant medications, comorbidities, and the level of dermatologic monitoring have not been studied.</ao:suffix>
    <pav:createdOn>2014-08-02 11:21:50 -0400</pav:createdOn>
    <ao:exact>The use of HLA-B*1502 genotyping has important limitations and must never substitute for appropriate clinical vigilance and patient management.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PHENYTOIN-8848de76-8d74-4620-bcc7-a86a596e5dd9.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ECAC2FA7-FAA7-485D-A99C-271BB5D62013">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3542</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>F5</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8AC02895-0398-4206-B5B8-5D394A99F4A7">
    <ao:suffix>.             </ao:suffix>
    <ao:exact>Initial Dosage\nThe dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\nâ\nÂ Â Â Â Â Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\nâ\nÂ Â Â Â Â Genetic factors (CYP2C9 and VKORC1 genotypes)</ao:exact>
    <domeo:uuid>8AC02895-0398-4206-B5B8-5D394A99F4A7</domeo:uuid>
    <pav:createdOn>2014-06-11 14:07:46 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8AC02895-0398-4206-B5B8-5D394A99F4A7"/>
    <ao:prefix>              </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0873D062-8063-4C54-9319-262761698F98">
    <rdfs:label>Not Important</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is not associated any clinically relevant pharmacokinetic with respect to the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:894FDE75-A8A2-4755-BD62-1F68865DA346">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PHENYTOIN-8848de76-8d74-4620-bcc7-a86a596e5dd9.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>894FDE75-A8A2-4755-BD62-1F68865DA346</domeo:uuid>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-08-02 10:57:23 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:894FDE75-A8A2-4755-BD62-1F68865DA346"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>There may be wide interpatient variability in phenytoin serum levels with equivalent dosages. Patients with unusually low levels may be noncompliant or hypermetabolizers of phenytoin. Unusually high levels result from liver disease, variant CYP2C9 and CYP2C19 alleles, or drug interactions which result in metabolic interference. The patient with large variations in phenytoin plasma levels, despite standard doses, presents a difficult clinical problem. Serum level determinations in such patients may be particularly helpful</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:381FDCEA-10CB-4947-87D0-FE1B7B9AF309">
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B1F18DEB-20C0-42A9-A17A-E9FFED4C4834">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB28026C-C47A-45ED-AA26-E514F6865F6C">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B64B9D8-3BE7-46A5-99E8-51142C33754A">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6DDB6699-6C27-41D4-AF1F-8A67A7691925">
    <pav:createdOn>2014-08-02 10:36:55 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FD368524-6F09-4376-AC8C-D75A9A387A2B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:099F3820-5DA9-4882-88DB-A3E01DF3B334</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:96A0F5F4-831E-46D5-8A29-337ED9DE5940"/>
    <pav:previousVersion>urn:domeoclient:uuid:FA69E566-5DB7-4914-9415-98DC8BFA5C08</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:0AF9E34D-BB35-4C4E-A120-D5B8F937F55A"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:983564B3-9258-48BE-8693-C04C2636E88E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-08-02 10:45:06 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:B4A46BE9-5408-46BA-9CC1-8B0430DC913D</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:11BB99CC-6A33-487D-B318-019C7709AEEF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:224663F4-07A0-4FBC-A16E-E7CC8E2BE4B3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:605401F9-CEC0-4386-9F96-10216E94DB09">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:802288B4-922E-4898-A87B-459F64B69564"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5BA002F2-35EE-4CE2-BCB7-FE83BF8FF7A5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E140DE6F-DDD3-4D85-86B9-5A73C2EEB94C"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:A5DB27A0-A0F6-4DAA-8AED-0377D85505FD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:94ADE34C-D689-4935-81C9-D5C7435911A2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7925A8BE-4401-4E13-A60C-0CFB0EFB7480"/>
    <pav:lastSavedOn>2014-06-01 18:56:28 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:22D1D12A-D376-4A58-BE50-04FA3F26EAA7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:146074E6-D887-4B6B-A91C-D2BF04FB29EE"/>
    <pav:createdOn>2014-06-01 18:56:26 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93A2E2AB-C559-4E1B-8F03-7A7C0F649F1C">
    <ao:suffix>. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:93A2E2AB-C559-4E1B-8F03-7A7C0F649F1C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMIPRAMINE-1827a5aa-733a-49d9-89d9-48ea0367b230.html</ao:hasSource>
    <domeo:uuid>93A2E2AB-C559-4E1B-8F03-7A7C0F649F1C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-08-04 13:44:58 -0400</pav:createdOn>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called âpoor metabolizersâ); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:154F154E-C935-4950-B467-6547CDB11B78">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B739B4CC-34BA-4E57-991E-731FFA9982BC">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clomipramine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01242</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4BB2FDDE-C596-4CB9-8B7E-813073101762">
    <pav:createdOn>2014-06-11 14:09:37 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:661F6C14-327C-4CB7-86D0-5549D22CDEC4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BD943268-375C-4FD3-BF66-1B7A4E7165D3"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:09EE5DFD-48E2-44AE-9A95-A4E230FED0C6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:9B9EF819-9039-486A-8EF5-D8EE4586786F"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CFC752CE-3983-465F-A490-55640D3A5AAD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DFF63EA5-24A8-454C-ABA1-468160F5E182"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-11 14:13:32 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FDD592F7-D463-493A-8912-1DCFCDFE4C3A">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>FDD592F7-D463-493A-8912-1DCFCDFE4C3A</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FDD592F7-D463-493A-8912-1DCFCDFE4C3A"/>
    <pav:createdOn>2014-06-01 18:08:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>ng codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. </ao:prefix>
    <ao:exact>Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BED33609-E929-4486-9EAC-0B963C21CC8F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BED33609-E929-4486-9EAC-0B963C21CC8F"/>
    <ao:exact>In human microsomes with specific CYP isozyme activity, CYP3A4 metabolized letrozole to the carbinol metabolite while CYP2A6 formed both this metabolite and its ketone analog. In human liver microsomes, letrozole strongly inhibited CYP2A6 and moderately inhibited CYP2C19.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:prefix>onide conjugate of this metabolite is the major pathway of letrozole clearance. Of the radiolabel recovered in urine, at least 75% was the glucuronide of the carbinol metabolite, about 9% was two unidentified metabolites, and 6% was unchanged letrozole. </ao:prefix>
    <pav:createdOn>2014-06-01 20:33:19 -0400</pav:createdOn>
    <domeo:uuid>BED33609-E929-4486-9EAC-0B963C21CC8F</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2FB69F2-D2FF-43EF-8D5C-29732917A825">
    <ao:body rdf:resource="urn:linkedspls:uuid:0873D062-8063-4C54-9319-262761698F98"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1A88FBF0-A260-4DEF-B583-5E9E8F918005"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7C478D95-94FE-474B-B9ED-AA77113212FD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:057E63DB-B25B-4E76-9FB2-B358F7686200"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7044D8AD-2E9A-4764-8005-C08DC9ACB3C5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:43BE40DF-E3A1-4B18-861F-5F151D1E6E92</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:46F6BA9D-79BA-48A7-91D5-BBFC46775697"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdOn>2014-06-02 11:47:03 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0E35AA6-356F-4054-945A-07801C6240FC"/>
    <pav:lastSavedOn>2014-06-02 11:47:08 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:451D05CA-4BB1-46B3-81DE-57753077DCC2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:82A863E2-4600-4792-BDAB-897D7BCBB8A7"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0D3B9099-D4D4-4D0D-BB45-DACEAE2FC2E3"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A51DC49-F45F-4CA3-A6F9-06104CA8B14C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:85062DD4-AC27-4671-801E-7592AC985BD2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:275605A0-79AB-4D06-9E3C-B817A21D1490">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <pav:createdOn>2014-06-01 20:46:16 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:275605A0-79AB-4D06-9E3C-B817A21D1490"/>
    <ao:prefix>Table 4 describes the characteristics of the breast cancers in the NSABP P-1 trial and includes tumor size, nodal status, ER status. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>.</ao:suffix>
    <ao:exact>Tamoxifen decreased the incidence of small estrogen receptor positive tumors, but did not alter the incidence of estrogen receptor negative tumors or larger tumors</ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A448D700-3F1E-4D64-870C-505840A1EC4E">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A2B59F5-E399-48B3-8649-CB2EC976CF97">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:19FFFAA8-45DF-4BF9-9289-281EBDF38F90">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:290A03B7-2778-43B8-8B8B-4F4F7547BA6B">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA7853CA-D5EE-4BB9-BFBA-7B46AEDB5250">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25AB90AC-C771-4406-977E-8DC2CA3E5DBE">
    <pav:lastSavedOn>2014-06-01 18:18:53 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:1491F2F7-B153-44DD-9D3B-6111C922E0AD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D2A4F1C-7ECF-457E-9105-89D4FAC2EAC4"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:38B40CF7-C8FF-4523-8FCC-9DD4D66AD8E0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:CAC3933D-809D-4D96-8DCB-B56002C53C71"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EFF7AFC3-9668-48B3-8D90-C3D7A5C411AE"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8C665A2A-70BA-4895-9351-8CB339A59707"/>
    <pav:createdOn>2014-06-01 18:18:53 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2623AB8-D307-4E32-8797-292B9D4C2A82"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A59BB6E-2551-4B9E-975A-64B9A8EA2B15"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CDAA9AA2-EF56-4941-8EA2-F8E33BC70076"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:A7D91F7B-78BE-4E99-9622-0C2007B1C76B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:39D8A7A2-CED4-47B5-BB61-961C7C6C891E"/>
    <pav:lineageUri>urn:domeoserver:annotation:EB9193A7-7211-4F58-A737-D51717F3E00C</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F46F596-3A3E-4B21-BBEA-8C8155F1DEC0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:52BAA8DA-2ECD-484F-A401-FC81FB13BC72"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EAF55A68-F83C-4EA3-ACCE-A7D22C0D74A8">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:852C6E07-7D0F-4759-B60B-2F84975DE3EC">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:43BE40DF-E3A1-4B18-861F-5F151D1E6E92</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D2D084F-6A5B-4E87-9B36-958F2E5BA705"/>
    <pav:lastSavedOn>2014-06-02 11:47:08 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:62C44EE7-9565-49BB-8348-F00484C13CA9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5F0D7FB-E816-4314-B450-214BD51BDA11"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C49E36DE-5ECE-4AE4-8054-4C31FF132938"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:563D84AA-9BEE-4BA8-8D08-3A4F5F473A1F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B590989-98A9-4FC3-9F06-44D7192C82FD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6894BC08-84DE-4272-B1B2-1CCDD5AF8ADD"/>
    <pav:createdOn>2014-06-02 11:40:20 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D2AE312-F185-429F-9003-FDA4E74523C6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AF6943C2-2D3C-4C53-9058-33F424A1D2C8">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1407863-3005-4220-AB14-446C3EC7B195">
    <ao:body rdf:resource="urn:linkedspls:uuid:ADC2C0BA-8531-4C8E-9016-F3E0BD15B5E3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:26386F6E-0E97-4ACB-AFBA-2C331A2E54E4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-01 20:37:15 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:59D463C5-ED0D-4FAD-8454-93F2D804878B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:854159CB-9EDA-4075-8EA9-8582AC113366"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:24EFE4BC-3895-4D41-9ACB-83753AC5B633"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:3FCC9F3C-187A-4D10-B907-FACC9E668E85"/>
    <pav:lastSavedOn>2014-06-01 20:37:20 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:06682B01-A432-4E05-8191-6DAD4683C330"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AA8627E-CA88-4386-8040-4A006B86F19F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:5B38A180-D6D0-4D80-BB8F-BE5F1F6BC3D0</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E84A315B-C921-4512-B11A-846BE09D8237">
    <pav:createdOn>2014-06-02 11:38:36 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E84A315B-C921-4512-B11A-846BE09D8237"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid>E84A315B-C921-4512-B11A-846BE09D8237</domeo:uuid>
    <ao:exact>Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablet therapy.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C355731A-4AB5-43C2-80F9-CBFB4F23B03D">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:870EBE5A-B94A-49FD-8FE1-0F574B19DB48">
    <ao:body rdf:resource="urn:linkedspls:uuid:3BA23D20-616C-4FB1-A929-A65950D7A2C3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC96A550-4FD5-41F2-AFF2-8D9B4B59855E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C085D6FD-C375-4444-ADF0-98B2C81E9630"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B40CB31-3B71-4F4B-813B-2D43EBE098D9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1DAE0D7E-358C-4CB1-8BFA-B6EE64B95E61"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:B615F670-F9AA-4781-B6AF-57B8D5543BAD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:D6A95D34-55A1-472A-A095-901E6BA00830</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:08D4AA9E-8ECC-4FCE-93FB-793BBFA64704"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E3E77A3F-21CC-4735-B88D-A04206FE0FE5</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB12F418-4C20-4529-9BFA-E4BEE2EFD420"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdOn>2014-06-01 16:53:27 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F58939EB-6E2B-4932-88D1-8FC70B17FF67"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:06DE3EA4-B6AB-42C8-B67D-69BCE813A97F"/>
    <pav:lastSavedOn>2014-06-01 18:02:06 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:38B40CF7-C8FF-4523-8FCC-9DD4D66AD8E0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A3EAAFCB-A332-4199-ACDD-37AE73358A81"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:668B908C-47F9-41AA-BBFC-1B1DF64553E6">
    <pav:lineageUri>urn:domeoserver:annotationset:D6A95D34-55A1-472A-A095-901E6BA00830</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C1A7B574-6E7C-4642-82EC-465847EBE679"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:38B40CF7-C8FF-4523-8FCC-9DD4D66AD8E0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4D2018B-33A0-45F5-87FC-D51E7B320CD3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:41D66BF8-B50B-49AE-9485-093AD9465BA2"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E3E77A3F-21CC-4735-B88D-A04206FE0FE5</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:F810FB25-3A57-4784-8C4E-A29CCA74AAB3"/>
    <pav:lastSavedOn>2014-06-01 18:02:06 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8F0B2FE7-F15F-416D-BDC2-34ABD491A06C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FDA62776-5111-4CFD-B790-89C343774C0D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-01 18:02:05 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:64D3B7C7-C42E-4D2D-A22A-EC0C09CD1FAA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4831C32E-AE3F-431D-AFED-F707745EA4D6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7A499F53-8865-41FD-8795-0FA09E5EB038"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:C4606DC4-9987-46D2-AA73-4BD4170A1631"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2DE75673-3411-4788-8A96-BA7CD4384E5B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE123E60-78DB-4994-B150-CB634849D239"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:834AA255-FB15-454F-98B9-72E0C8AA687F"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8971A30A-BBAC-483C-9EFB-611514C47902">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:0EB463AE-2287-43F0-8DA1-DD1C572AC24D">
    <pav:lastSavedOn>2014-08-02 11:21:57 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:A33D4792-44D2-4D0B-9B6F-CA45CCA0C599"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PHENYTOIN-8848de76-8d74-4620-bcc7-a86a596e5dd9.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:3DC3EFBE-E013-4100-9C6D-51D5D6DC4B0F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4DA68686-16C0-452D-A86A-A699696AE167"/>
    <permissions:permissions rdf:nodeID="Nefd281b91f734fb5983416885121f93d"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:EE812AE1-C75A-4512-A501-E26A3E4C1E40</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:6707936B-B034-40C7-A346-23690C8AC370"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:71B7FD8A-6228-4731-AF24-2D540BA16DC1"/>
    <pav:createdOn>2014-08-02 10:50:49 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629ce3c370001"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <pav:previousVersion>urn:domeoserver:annotationset:8912FAAB-5D6A-451C-9FA4-2229D724E67C</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6A60543-E70E-4659-BE33-475B15815CF3">
    <sio:SIO_000111>(34073-7) DRUG INTERACTIONS</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34073-7) DRUG INTERACTIONS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:59D463C5-ED0D-4FAD-8454-93F2D804878B">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>endogenous estrogen
aldosterone
thyroid hormones
thyroid 
adrenal corticosteroid synthesis
hormone replacement therapy?</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:691466C3-C16B-4654-9676-C6ABADBA26D8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC5244F5-E70F-46C2-80A7-DA06EB1332C9"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:FE1C623C-2CC3-43AB-B533-3C6D3C2D63A1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FD3371AC-2CA4-4591-9FDB-F3F12C3F791F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CAB1083A-95FB-4729-BB49-0C452F7641BC"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:392AFCDB-F75F-4C2C-9BB4-8A27A839D13D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-11 13:59:16 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:534AC637-5CB9-405F-89FB-37DE9E223EA1"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <pav:lastSavedOn>2014-06-11 14:00:01 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:0D08AF10-4994-4093-B539-D39E81A9D03F</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8875C6FE-DBD8-404E-8B48-04D200BEEFF9">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>extensive-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#extensive-metabolizer</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8D60E72-87CF-4F20-8B7F-3DE216B184DD">
    <ao:suffix> Among these patients, 54% had node-positive disease and 46% had node-negative disease.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) conducted worldwide overviews of systemic adjuvant therapy for early breast cancer in 1985, 1990, and again in 1995. In 1998, 10 year outcome data were reported for 36,689 women in 55 randomized trials of adjuvant tamoxifen using doses of 20 to 40 mg/day for 1 to 5+ years. Twenty-five percent of patients received one year or less of trial treatment, 52% received 2 years, and 23% received about 5 years. Forty-eight percent of tumors were estrogen receptor (ER) positive (&gt; 10 fmol/mg), 21% were ER poor (&lt; 10 fmol/l), and 31% were ER unknown. Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone.</ao:exact>
    <pav:createdOn>2014-06-01 20:26:55 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E8D60E72-87CF-4F20-8B7F-3DE216B184DD"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D9A48574-7F84-4D1C-B3B1-C7F5BD271B81">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:77163E48-FDB2-4C0A-A127-B74C2095634E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8840FB3B-47B3-4958-864C-619B7A4F6927"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:82B4B70A-A7ED-4A04-9BB4-206EF37C2508"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:05EA9C6C-754C-4764-A879-E4CE913428A2</pav:previousVersion>
    <pav:lastSavedOn>2014-06-01 20:12:32 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5CD1AE27-AFD2-4F5F-BF55-2EE63DF53514"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C856BE8E-DEA3-4EBC-BAE5-826826C36CF9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:45BA0CBA-7217-4D45-8C6B-F3247F353A9F"/>
    <pav:createdOn>2014-06-01 20:12:29 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8C6C1DB3-50EA-4E8C-9744-0620557B06F4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB12F418-4C20-4529-9BFA-E4BEE2EFD420">
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ADF704DF-FD54-4F7D-8FA6-AD2051EF604A">
    <ao:body rdf:resource="urn:linkedspls:uuid:2CD32F7C-E76A-467D-8B6E-40F20B070501"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:70D9843F-2457-40EE-B7FF-821A778215A9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E09C5817-9861-40D2-88DF-8866F982C841"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4844EC40-6C77-44B8-AE51-379D6331DEFE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F44327B4-A42F-460E-9D93-C700B8391D1D"/>
    <pav:createdOn>2014-06-11 13:49:48 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:309964A6-727A-4B76-9D79-9E7DCF57399A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:DADF2D2C-AA34-4339-B24C-5E885726DE31</pav:previousVersion>
    <pav:lastSavedOn>2014-06-11 13:57:33 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:AD5492F7-2EFF-4A23-AE94-6DFD182D578B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DBE7CD7-EA07-4F4D-9250-FB8471CE8D1E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:FA23F89C-894F-406C-ACB1-E2C29861E5CA">
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629ce3c370001"/>
    <pav:previousVersion>urn:domeoclient:uuid:AA8FB219-6891-421B-B530-36EA46A91A70</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-08-04 13:37:58 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9075139C-C17E-487B-BDFB-2F87609BC9B9</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/NORTRITYLINE-e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Nea5bffa91b74453aa04555d7180f2802"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:16729159-3AAD-4126-B53D-A07E34E336FE"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2014-08-04 13:36:27 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:DCA0B486-3C63-4659-B871-8278B4945126"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39D8A7A2-CED4-47B5-BB61-961C7C6C891E">
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdfs:label>Prodrug</rdfs:label>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:910AE070-EF69-4580-8FA8-D6AC65D9B23F">
    <rdfs:label>VKORC1</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4844EC40-6C77-44B8-AE51-379D6331DEFE">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFC752CE-3983-465F-A490-55640D3A5AAD">
    <pav:createdOn>2014-06-11 14:09:37 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Initial Dosage\nThe dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\nâ\nÂ Â Â Â Â Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\nâ\nÂ Â Â Â Â Genetic factors (CYP2C9 and VKORC1 genotypes)</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CFC752CE-3983-465F-A490-55640D3A5AAD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>An INR of greater than 4.0 appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of bleeding.  </ao:prefix>
    <domeo:uuid>CFC752CE-3983-465F-A490-55640D3A5AAD</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ADC2C0BA-8531-4C8E-9016-F3E0BD15B5E3">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:507F466D-7AFA-483A-882D-799FA2A7E893">
    <ao:item rdf:resource="urn:domeoclient:uuid:99B319B0-E8D9-4249-B5BB-364D474CC619"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5F57EB18-DEBF-48FA-BE9E-0343092EC802</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lastSavedOn>2014-08-02 11:36:55 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/VORICONAZOLE-ce3ef5cf-3087-4d92-9d94-9eb8287228db.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>urn:domeoclient:uuid:53161EFD-DC60-4287-BE6C-44D37ACEC807</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:667FCDCB-0393-4E60-8D6D-855F640CC6B4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2014-08-02 11:27:59 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629ce3c370001"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <permissions:permissions rdf:nodeID="N0d6be00b8db54fa5a9348515f28d3f3d"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AB47130D-2050-4DE9-A0B7-7D893485F387"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:105FB6F1-709B-4409-B416-BAF13AAAAFE4">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C340683-6435-4DF4-95F9-ABF7890994C6">
    <pav:createdOn>2014-06-01 18:10:46 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1C340683-6435-4DF4-95F9-ABF7890994C6"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1C340683-6435-4DF4-95F9-ABF7890994C6</domeo:uuid>
    <ao:suffix> Codeine is contraindicated for post-operative pain management in all pediatric patients undergoing tonsillectomy and/or adenoidectomy </ao:suffix>
    <ao:exact>Respiratory depression and death have occurred in children with obstructive sleep apnea who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1378C98-3880-453B-8C8E-7C875F23A8C8">
    <pav:createdOn>2014-06-02 11:20:27 -0400</pav:createdOn>
    <domeo:uuid>D1378C98-3880-453B-8C8E-7C875F23A8C8</domeo:uuid>
    <ao:exact>Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.</ao:exact>
    <ao:prefix>lite found in patients' plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D1378C98-3880-453B-8C8E-7C875F23A8C8"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C243EC9-2225-4772-9FAC-3D93C17E4CAF">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:69D70A19-BD83-4C1B-BE23-D5B62C7C1389"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC00101D-0828-425E-8C39-55A240DC2F1E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:32E1E9EA-32B8-460F-B557-2CA8E3B4CC01"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5DD7301F-B239-42ED-8AC3-535CF0C77261"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AF079F40-0025-456F-8288-81DF3604F1DA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B667F421-8E8F-44D2-9A57-4CC1AEDC2893"/>
    <pav:previousVersion>urn:domeoserver:annotationset:370AB788-B410-4EF4-A015-06EEAC3F3446</pav:previousVersion>
    <pav:lastSavedOn>2014-06-01 20:20:47 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:246FC7F0-0FDD-4242-9C08-71340FAEBED2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-01 20:15:14 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:76EA7D30-E3C4-4197-A7B4-293995F38E7C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:71923767-C4E7-42DE-84F8-01605D56F151"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:5999E193-A258-4C6E-8E0E-1460FC80FFD4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:099F3820-5DA9-4882-88DB-A3E01DF3B334">
    <pav:lastSavedOn>2014-08-02 10:45:06 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:B4A46BE9-5408-46BA-9CC1-8B0430DC913D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Nbcb582457d94416da18b28bd7cfca1c4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4F2AE4E6-A6F9-4246-ADB2-188722E20D2A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6DDB6699-6C27-41D4-AF1F-8A67A7691925"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0804F2E0-3D85-4B4E-8C0E-77594705659F"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:A8EF3F42-DA4C-4260-B12B-9631A0C9D67E</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629ce3c370001"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2014-08-02 10:32:06 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B12F04A-876C-40C2-BD49-80D7A1174AE8">
    <poc:Comment>can this statement stand alone?\n</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9360526-75C3-4E43-A4ED-13FB7F93DB8B">
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A9360526-75C3-4E43-A4ED-13FB7F93DB8B"/>
    <pav:createdOn>2014-06-11 14:11:30 -0400</pav:createdOn>
    <ao:prefix>CLINICAL PHARMACOLOGY and PRECAUTIONS ). </ao:prefix>
    <domeo:uuid>A9360526-75C3-4E43-A4ED-13FB7F93DB8B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DB320B68-62FC-4457-B449-7E0CD9890D51">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2936B938-6AC4-43F5-BFC2-4E299D5E7DA8">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DFA36CF5-82DD-42C0-8AEC-980D7F409410">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DFA36CF5-82DD-42C0-8AEC-980D7F409410"/>
    <pav:createdOn>2014-06-01 20:43:33 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:suffix> In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estr</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1B0F964-275B-4CDF-B35A-A2702316A71A">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:698DED5B-0966-49DB-A5A0-88E02DBD1E0B">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D281CDBD-9057-40C6-9414-F16357D3042C">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7DD80216-E6DB-48BD-A9C1-D37C6D156E4F">
    <sio:SIO_000111>(34073-7) DRUG INTERACTIONS</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34073-7) DRUG INTERACTIONS</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E3BC098-863B-4FD1-9E5F-F4C244D690CD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:565AEAAE-A8AF-4293-9777-49B61816D057">
    <rdfs:label>Phenytoin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00252</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22D1D12A-D376-4A58-BE50-04FA3F26EAA7">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53B65C14-B175-4B68-977D-5FA1B2135BF6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:53B65C14-B175-4B68-977D-5FA1B2135BF6"/>
    <pav:createdOn>2014-06-11 13:29:37 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>CYP2C9 GenotypeNS-Warfarin Clearance/Lean Body Weight(mL/min/kg)Mean (SD)**SD=standard deviation.p&lt;0.001. Pairwise comparisons indicated significant differences among all 3 genotypes.*1/*11180.065 (0.025)*1/*2 or*1/*3590.041 (0.021)*2/*2, *2/*3or *3/*3110.020 (0.011)Total</ao:exact>
    <domeo:uuid>53B65C14-B175-4B68-977D-5FA1B2135BF6</domeo:uuid>
    <ao:suffix>188Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9 and *11 alleles in Caucasians</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E83172CC-7BFF-4FCF-988A-B61E2C95A210">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53F71014-8A27-4415-B21D-AFF704D17012">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>Among these patients, 54% had node-positive disease and 46% had node-negative disease. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:53F71014-8A27-4415-B21D-AFF704D17012"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-01 20:29:42 -0400</pav:createdOn>
    <ao:exact>Among women with ER positive or unknown breast cancer and positive nodes who received about 5 years of treatment, overall survival at 10 years was 61.4% for tamoxifen vs. 50.5% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 59.7% for tamoxifen vs. 44.5% for control (logrank 2p &lt; 0.00001). Among women with ER positive or unknown breast cancer and negative nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p &lt; 0.00001).\nThe effect of the scheduled duration of tamoxifen may be described as follows. In women with ER positive or unknown breast cancer receiving 1 year or less, 2 years or about 5 years of tamoxifen, the proportional reductions in mortality were 12%, 17% and 26%, respectively (trend significant at 2p &lt; 0.003). The corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend significant at 2p &lt; 0.00001).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13F6F038-D121-476D-B1F0-BC33B90EC49F">
    <pav:createdOn>2014-06-11 14:05:16 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:40EA8DAC-237D-401C-ACD3-F0B22A66F340"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1B0F964-275B-4CDF-B35A-A2702316A71A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:9786ADCE-5FC9-4221-9B84-DAE631C0959B</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:72F5818D-704A-4D56-AAD9-5D5D51E6E7F8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1A3D5CE0-5494-41FF-93AA-12BE6B105CB5"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6646F47-309F-4535-A926-D22F26209907"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE360A0D-A297-40DC-936D-5F5D1222846C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:0838B265-A37E-4346-BF96-4C054DFB84AD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5F042007-B403-4C62-853D-9924A699BD58"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4AD4C0A2-0B16-4B3E-A064-02C1FAD359BE"/>
    <pav:lastSavedOn>2014-06-11 14:13:32 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6207BDE-B892-441F-BE0A-0D7E3B0CC6B7">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9DA5C585-5B84-4456-A50C-125561E7BB6A">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:24704269-377D-49A6-8790-1E8DF7BCE2B1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>dihydropyrimidine dehydrogenase (DPD) deficiency</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:994E0CF7-0D24-46F2-9307-D7615779EC81">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6707936B-B034-40C7-A346-23690C8AC370">
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-08-02 11:21:50 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0EB463AE-2287-43F0-8DA1-DD1C572AC24D</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:lastSavedOn>2014-08-02 11:21:57 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:565AEAAE-A8AF-4293-9777-49B61816D057"/>
    <pav:lineageUri>urn:domeoserver:annotation:340F9CD7-40E7-4E92-B67E-64E4E5E9AB18</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:5730BC6B-404B-44A7-A80D-CF0CBBE7E8EA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0BCB85F-4E9F-490F-A26B-7F167BCFBF49"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA97D38E-6D70-4646-8118-00559556A4D4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C44D8A99-C64C-4B6C-A7B2-838CCA24F46A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:739A5BD0-8B81-4858-8716-A365FFDAC30C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2672E598-EC59-4170-9CB6-E1E32412FAF5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F7CD8925-D7A3-41BD-B804-02AAEAF23F8A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CEA75987-4FBD-47E3-870C-867538E5366B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBD4128C-C218-48F8-BFBF-7A78F47CA224">
    <pav:createdOn>2014-06-11 13:34:10 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:106ABB0B-6E1C-4AF2-9606-A390F46EBE96"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E7424CE2-FD6C-4DBC-BFB5-42DA271DD71D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-11 13:35:04 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:0236F550-A39D-490D-B4BD-21E191A6AD30"/>
    <pav:previousVersion>urn:domeoserver:annotationset:544466F7-3BAA-402F-8D8F-EAB6AA612F2E</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:21F0DD09-9A9B-44AA-B511-DECE65073BED"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A3B7CD1C-EC13-4838-97A4-28E96CFBABA2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:606F71C5-8ED6-4EA0-8F3A-1EFA695FBC76"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:D27F296F-4104-4FB6-910F-4B5BD4D67EA1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:169A7E8A-4D12-410C-81E5-561DCA16974F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A354BAB4-08FF-4889-889F-705F226C1E47"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71B7FD8A-6228-4731-AF24-2D540BA16DC1">
    <ao:body rdf:resource="urn:linkedspls:uuid:FAB26198-EF81-4447-AB54-8786FC5EDE47"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:894FDE75-A8A2-4755-BD62-1F68865DA346"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2EC9FFBC-39E6-4792-A7DA-C8D1C024066E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0EB463AE-2287-43F0-8DA1-DD1C572AC24D</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA789C7F-D6A1-414F-BC74-A37C3C396513"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:77A4C9B5-BEEE-43A9-B8F4-6B4BC1533760"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-08-02 10:57:23 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:606B5431-4B53-4BD3-9EAE-394BFF580265"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-08-02 10:57:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:91D240AB-DFAF-4F14-BE22-B6B70925677A"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:EE812AE1-C75A-4512-A501-E26A3E4C1E40</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE7B9DF8-FB55-40CF-8FDC-9314444F8486">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F58939EB-6E2B-4932-88D1-8FC70B17FF67">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DCA0B486-3C63-4659-B871-8278B4945126">
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:3A41F800-6313-4209-8FC6-6A15248F96DC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7C8DABC-CB6B-4C4F-8514-4FA6E4C2B5D1"/>
    <pav:lastSavedOn>2014-08-04 13:37:58 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B34B407B-DA7B-48C1-A77E-AC097227B8B5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:18576D93-9B30-4D84-A45D-3448E7139E8E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:5A474F9B-72D8-4812-A11D-7ECC770275F5"/>
    <pav:createdOn>2014-08-04 13:37:54 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DACE1DF5-0195-433D-951A-A7CBDCE6CEAA"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FA23F89C-894F-406C-ACB1-E2C29861E5CA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D4679C4-24B9-4A12-AE7A-6EF360A93822"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3DA0ACFB-DBE3-4670-9096-B2693120E22D"/>
    <pav:lineageUri>urn:domeoserver:annotation:EC623E97-2E0F-4B1E-B424-890A5FF4E508</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50D1081C-CDDB-4751-AE94-76783A520183">
    <ao:body rdf:resource="urn:linkedspls:uuid:46515176-CB42-4873-966D-0A5D67496F43"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:965254E7-B87D-4A3D-A34F-21420503EE36"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B1F18DEB-20C0-42A9-A17A-E9FFED4C4834"/>
    <pav:createdOn>2014-06-01 15:33:12 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:94089BCA-C215-4C7B-A9A4-7683F963DE3D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:38B40CF7-C8FF-4523-8FCC-9DD4D66AD8E0</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:E3E77A3F-21CC-4735-B88D-A04206FE0FE5</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A2B59F5-E399-48B3-8649-CB2EC976CF97"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2070AEB-1F92-495D-B89F-7C4754BFDE8D"/>
    <pav:lastSavedOn>2014-06-01 18:02:06 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C2415F89-08E6-49E1-8F21-8500F57364A5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7520CD5-1D2F-4FE1-ACDB-BA5AF054911F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:49158C09-A374-4459-AC9A-A986E180C807"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D4C0D8A-FED7-4829-92D0-676FF52D8604"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D6A95D34-55A1-472A-A095-901E6BA00830</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:25DBAF85-B124-422C-A1DD-13CA32E00C26"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:765BDF55-5CD5-41A1-90E1-CCA6B2630B53"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F0B2FE7-F15F-416D-BDC2-34ABD491A06C">
    <ao:exact>Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications denoted as *1/*1xN or *1/*2xN). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing)</ao:exact>
    <domeo:uuid>8F0B2FE7-F15F-416D-BDC2-34ABD491A06C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix> </ao:suffix>
    <pav:createdOn>2014-06-01 18:02:05 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8F0B2FE7-F15F-416D-BDC2-34ABD491A06C"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6AA7F636-6F42-4B80-841F-F2B140D5A4DA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>ambiguous when taken  a whole this label. previous statement with n=81 indicates no impact, whereas this says nothing is known.

HGNC Biomarker need to be changed</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52BB9789-9B14-4A35-8B25-A6925CF15C47">
    <domeo:uuid>52BB9789-9B14-4A35-8B25-A6925CF15C47</domeo:uuid>
    <pav:createdOn>2014-06-11 14:11:03 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:52BB9789-9B14-4A35-8B25-A6925CF15C47"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>.</ao:suffix>
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C79C7D5-64C2-45DF-8C42-86AFF653590C">
    <ao:context rdf:resource="urn:domeoclient:uuid:D296E2A7-2EC2-4235-B5FF-1E4E1D76F5D4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:61A57170-940C-49B8-8EAE-7336CF202D8E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:48BF451F-8ED4-4DCE-BA4E-2A7F92633EAE"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:6420B306-74DB-455D-BE43-AFBC96ACA818"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5486F7DE-A8BF-4A3F-B93C-84D5BCD1F383</domeo:belongsToSet>
    <pav:createdOn>2014-08-04 13:31:48 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C1B6E5EA-2C52-46E8-A53F-9B074F8E312B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B739B4CC-34BA-4E57-991E-731FFA9982BC"/>
    <pav:lineageUri>urn:domeoserver:annotation:CAE37171-DE41-4E26-B15B-3C2B46C43D40</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:F97789E5-114B-431A-A577-9E031BDACDA4"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-08-04 13:31:50 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F15080E5-46CA-41ED-8B36-0985F56D56BF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84DB5EC5-B980-4493-82E8-5E5D393FE2D9">
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:createdOn>2014-06-01 20:55:48 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:FD140441-800B-4DD9-BDDD-A11517ACBE7F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB7F5CE5-2A4D-469D-82B4-26C64B9D23AD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ECAC2FA7-FAA7-485D-A99C-271BB5D62013"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:44301F97-7088-46C4-BB32-27D413FE3A60"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B901F682-13D1-4291-9125-3CD610827426"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4BD57CF8-1480-405E-BA53-593A3F7CA86F</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:DBEB0ACB-D1CB-409F-8826-3D87E728DE4C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:F18EABFA-DE53-4697-A79C-CE2728D2CEAF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:04539A04-F082-4C33-9B14-C8B5A2B0E0B5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-06-01 20:55:49 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5730BC6B-404B-44A7-A80D-CF0CBBE7E8EA">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5FD6BB9F-D38A-4E21-A7F7-F53FB5B3CE93">
    <ao:body rdf:resource="urn:linkedspls:uuid:F2632350-81DF-4377-8B1B-40C64610E1A3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA36C067-E5FD-411F-9D92-749CA81A5155"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4764A669-C758-4E31-AD1E-44C1AA6CE798</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:38B40CF7-C8FF-4523-8FCC-9DD4D66AD8E0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:7065589B-D53D-4313-BEC7-33FABA8CE2E6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:95A76A81-86B0-46DB-A84C-D2B04F69E41B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E33A87B-4D10-4EEB-9474-B2DE755BB787"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:FDD592F7-D463-493A-8912-1DCFCDFE4C3A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC49AA35-6797-474A-BB56-1839ED9472BD"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:D6A95D34-55A1-472A-A095-901E6BA00830</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:DED2EDC8-D32C-4BEC-B3D0-8F766D1566B4"/>
    <pav:lastSavedOn>2014-06-01 18:08:56 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C8642430-877D-4F0B-8ED2-032AF7428A76"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:363BDC0B-DE13-492B-A8A9-813EB5CD33BF"/>
    <pav:createdOn>2014-06-01 18:08:55 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C647CEF6-6BF9-4822-89CB-25C5E2F54D09"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DEBF1763-8E56-4EA1-AEAF-BBCA6E565663">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:81252757-46D6-4D29-93CB-6BE7FED5A9A4">
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4EECF41-92BE-4099-9881-B076F4CAE1D8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>respiratory depression, death, obstructive sleep apnea, tonsillectomy, adenoidectomy, </poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2524015E-FEBC-411E-BE2E-CD1735991ABE">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:62084687-82BB-4416-B629-C03B05181B86"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5AD7DDEE-BB3F-4435-8859-1FC48608C0DC"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5E5439B7-EE16-4080-9092-7E25F09413EA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:479A731B-392C-41AA-8F76-401D07ECF42F"/>
    <pav:lastSavedOn>2014-06-11 14:13:32 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:13A9663E-FDF9-4AF9-94C4-DFCC2515F45C"/>
    <pav:lineageUri>urn:domeoserver:annotation:B65DB754-8ED0-46C4-BC19-FC0D5941B981</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <pav:createdOn>2014-06-11 14:12:45 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:270B3E60-81BB-473C-AA87-E68F2FB9938D">
    <rdfs:label>Phenytoin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00252</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0EAF3C37-B91B-4D02-889E-1FAD55EA1307">
    <ao:body rdf:resource="urn:linkedspls:uuid:420A7745-DFE2-4507-BB59-E65C8E96F633"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <pav:lastSavedOn>2014-06-11 13:29:53 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:53B65C14-B175-4B68-977D-5FA1B2135BF6"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2322D8A4-E687-416C-A663-2B4F6EB929F7</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E9B1D3D-0924-43C5-9276-ED74DEE57EF3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2AF296C4-A33C-48D1-A5AE-B53A4462F7E5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E817B0C6-D55A-458C-834F-E3108A61E647"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-11 13:27:12 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:83CD3AC9-0F79-45ED-B263-CC7B66B0454D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2ADEE0A-98B3-4299-980C-3EBF27CC5983"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A5CFBDE8-6046-48AB-B4B8-ADFE7C6BE368"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:36E46813-19B9-4E7A-B494-DC44E7E77A5C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A3DC838-7F98-44F7-B8BE-DB357CB2F83F">
    <ao:exact>Tamoxifen decreased the incidence of small estrogen receptor positive tumors, but did not alter the incidence of estrogen receptor negative tumors or larger tumors</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. In women with breast cancer who are at high risk of developing a second breast cancer, treatment with about 5 years of tamoxifen reduced the annual incidence rate of a second breast cancer by approximately 50%.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A3DC838-7F98-44F7-B8BE-DB357CB2F83F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <pav:createdOn>2014-06-01 20:57:33 -0400</pav:createdOn>
    <ao:prefix>). Women should understand that tamoxifen reduces the incidence of breast cancer, but may not eliminate risk. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A8C6206-5882-423D-B3A3-28502F8548C3">
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:8971A30A-BBAC-483C-9EFB-611514C47902"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:91136920-A36A-4336-B15B-F7BD77B74823"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E2D29067-AA5B-46D8-9CFF-9C566C9441E9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lastSavedOn>2014-06-11 14:00:01 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:CB813A63-3B67-4CF1-851E-23758D0439A8"/>
    <pav:createdOn>2014-06-11 14:00:00 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:76AD476F-C289-424C-B080-FF9FDC1BB77A"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:0D08AF10-4994-4093-B539-D39E81A9D03F</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1DCFD255-484A-4994-8EF6-3AA59A2BB3E5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F042007-B403-4C62-853D-9924A699BD58">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>) and long duration of warfarin therapy. </ao:prefix>
    <pav:createdOn>2014-06-11 14:05:16 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5F042007-B403-4C62-853D-9924A699BD58"/>
    <domeo:uuid>5F042007-B403-4C62-853D-9924A699BD58</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e14304628d4c0014629ce3c370001">
    <foafx:email>wwilson624@gmail.com</foafx:email>
    <foafx:middlename></foafx:middlename>
    <rdfs:label>Will W.</rdfs:label>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:name>Will W.</foafx:name>
    <foafx:title></foafx:title>
    <foafx:homepage></foafx:homepage>
    <foafx:lastname>Wilson</foafx:lastname>
    <foafx:firstname>William</foafx:firstname>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3FB4857C-421D-40CB-ADB0-1EB479BFE4AB">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:54CE33AC-544A-4F34-AE24-72F464099576">
    <ao:suffix> (Table 1).2</ao:suffix>
    <pav:createdOn>2014-06-11 13:29:15 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:54CE33AC-544A-4F34-AE24-72F464099576"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid>54CE33AC-544A-4F34-AE24-72F464099576</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The variant alleles CYP2C9*2 and CYP2C9*3 result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively1. Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A3B7CD1C-EC13-4838-97A4-28E96CFBABA2">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF914CBA-27EE-4C33-A929-F5D51EED1623">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:667FCDCB-0393-4E60-8D6D-855F640CC6B4">
    <ao:body rdf:resource="urn:linkedspls:uuid:34A8CD45-16CD-4C75-9AA8-BB2B781A2681"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:createdOn>2014-08-02 11:29:32 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:507F466D-7AFA-483A-882D-799FA2A7E893</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E1DED8FC-F1B0-4719-B4F7-E38CF857E3CE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9B637F2E-1396-48B0-A39F-67DC22C2A984"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5F57EB18-DEBF-48FA-BE9E-0343092EC802</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:5CD3D25D-A767-4D5F-BBDC-A128401A7E65"/>
    <pav:lastSavedOn>2014-08-02 11:31:56 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:730E95BC-4718-48A0-9740-1B5D55D77A40"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A435508A-E2FE-45FB-9A4B-0CDD1F6028F1"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:AF45D32B-2C77-47D2-A0CC-3F4EB3D7B129"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EDE6ABED-333B-4E42-81E0-6413B330BE7B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C588CD5A-BCC0-4B89-B85B-C0C91E3D4EA1">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:69D70A19-BD83-4C1B-BE23-D5B62C7C1389">
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A6302C7-8EF3-460C-B116-7E59FA9BE9DC">
    <ao:body rdf:resource="urn:linkedspls:uuid:B9704426-CE3F-49D8-B1BA-14F8EDD6988F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:F9F7D401-954A-4681-9DCF-4774DD0355CE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:294D1B8B-6C69-42C3-B2E0-9A4F3FD352CC"/>
    <pav:lastSavedOn>2014-06-02 11:34:25 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F756ED20-FA04-4BDF-BC09-9FBC85BDC887"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AE07F18F-F19C-4F49-975C-232A47227ABA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A18AC49-4F82-4AE2-B58C-9068D4CE2A8B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:402EEAA2-F9CC-46AF-9550-E45E115692FE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D032294E-CED1-410A-B8D7-381F84967E05"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:CEF2E37B-C0A4-4F4B-A2A8-38BEC4B8DD44"/>
    <pav:createdOn>2014-06-02 11:33:05 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:A2165F85-DA12-4AC2-A372-6EBD213B5987</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B590989-98A9-4FC3-9F06-44D7192C82FD">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06DE3EA4-B6AB-42C8-B67D-69BCE813A97F">
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E02AB2A-7ABF-4839-ABFD-6DEFF552645D">
    <ao:body rdf:resource="urn:linkedspls:uuid:00D39640-85A6-4258-99D9-2F6F990A7699"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:AF6943C2-2D3C-4C53-9058-33F424A1D2C8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:A805FD4F-A44F-480F-A4FD-7BB2C11717E3</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:93A2E2AB-C559-4E1B-8F03-7A7C0F649F1C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6FC4169-F8BF-4EA8-BC45-49CD447A8225"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:18C88D86-53DA-4CD6-A6D4-DFADB6C6362D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE8E5AB7-DFBA-4CD5-8C65-EF0F085A6F8B</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:3798B8E0-BE90-4DE0-BCFB-27A121124827"/>
    <pav:createdOn>2014-08-04 13:44:58 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:94D2C52A-7138-4F35-91ED-9246F840B00C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-08-04 13:45:00 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:88108367-19A1-4D00-B6EB-78B390C12A84"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:938EE41D-651C-41ED-8C34-DD86053E22CF">
    <ao:body rdf:resource="urn:linkedspls:uuid:E83172CC-7BFF-4FCF-988A-B61E2C95A210"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5C205E24-92C4-484F-9EAE-03E0827A96AF"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D6A95D34-55A1-472A-A095-901E6BA00830</pav:lineageUri>
    <pav:createdOn>2014-06-01 18:07:18 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2830055A-ACED-40B1-B6C6-27369CCE01C6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C2CCDBA6-0295-4B86-8110-E1D72B2564B5"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:4764A669-C758-4E31-AD1E-44C1AA6CE798</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F0FFB28-D438-4B2B-BE87-A1AD3D082C02"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:38B40CF7-C8FF-4523-8FCC-9DD4D66AD8E0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:46FF888B-BFA9-44D7-9252-A859CD65C03E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A82CF14A-DCB1-4B86-8F03-654B6F950040"/>
    <pav:lastSavedOn>2014-06-01 18:08:56 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B188F4B3-BEE4-4198-BC13-07F018492D84"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:154F154E-C935-4950-B467-6547CDB11B78"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A270632-99AC-42BD-BA80-93F264DC803C"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB698F46-FE25-4759-8C5B-29163BA02518"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A7D91F7B-78BE-4E99-9622-0C2007B1C76B">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:66381541-3A38-429C-A287-E2B9DE4381F2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7BEDD80D-4265-4FCA-A0AD-DCC8A5047302">
    <ao:suffix>.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7BEDD80D-4265-4FCA-A0AD-DCC8A5047302"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Tamoxifen citrate tablets are a prescription medicine that is like estrogen (female hormone) in some ways and different in other ways. In the breast, tamoxifen can block estrogen's effects. Because it does this, tamoxifen may block the growth of breast cancers that need estrogen to grow (cancers that are estrogen- or progesterone-receptor positive)</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-06-01 21:01:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:246FC7F0-0FDD-4242-9C08-71340FAEBED2">
    <rdfs:label>Required</rdfs:label>
    <dct:description>A required test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.1alpha-050">
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <foafx:version>2.1alpha</foafx:version>
    <foafx:build>050</foafx:build>
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:homepage></foafx:homepage>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:392AFCDB-F75F-4C2C-9BB4-8A27A839D13D">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CE4DF44-922B-4B4F-9E0E-28118340C6C7">
    <pav:lastSavedOn>2014-06-01 21:05:20 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:724D3B35-67C5-43A4-BC96-46E359B92EE8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:7BEDD80D-4265-4FCA-A0AD-DCC8A5047302"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:945AB3F9-D117-4A09-A4D4-85964D29ACAC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E118AF70-C2CB-42BF-9C66-805D9273A823"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:60B2FC2A-0FCD-47E1-8AF6-036903D2D8FE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:26FC75F4-DD53-4BA3-BAE1-B9F1BF18603C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-06-01 21:01:27 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1056089-0FB5-44D2-A976-B96EE2910380"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4FDB6D9-6003-4748-9F44-DAD96C90C75E"/>
    <pav:lineageUri>urn:domeoserver:annotation:DF1D873F-A2EA-43B8-A80C-4117D7771126</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E80F8715-EB61-449E-A924-4D82E72F059E">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34068-7) DOSAGE AND ADMINISTRATION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34068-7) DOSAGE AND ADMINISTRATION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A33D4792-44D2-4D0B-9B6F-CA45CCA0C599">
    <ao:body rdf:resource="urn:linkedspls:uuid:6F6360F7-C764-4F07-977F-14703344B18A"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:EE812AE1-C75A-4512-A501-E26A3E4C1E40</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:C9F41C01-9838-4DD1-9996-CB3C12F77BCF</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:1488A565-393F-4193-95C9-2E2B6E284AFD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:270B3E60-81BB-473C-AA87-E68F2FB9938D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:6131A582-34D6-47BE-A4E5-C616495886DB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:69FCE2CA-34CA-475D-998B-7830A6F1026B"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-08-02 11:20:24 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C195A24A-0326-4ED5-8DAD-5D759C334633"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD865684-8CE5-4ED5-AA78-F871917481B3"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:06E2B901-88BC-4FE4-878C-CDD6CF4D6B0E"/>
    <pav:createdOn>2014-08-02 11:20:18 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0EB463AE-2287-43F0-8DA1-DD1C572AC24D</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00356E6C-B77F-47B4-9089-E756E1C8F1CA">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:00D3633A-8196-4872-83DB-5800718FB971"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7240E388-B7B2-4EC5-9469-402AAC33AFF4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B51718B4-5A16-4E25-86C6-63E480554AE3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:66381541-3A38-429C-A287-E2B9DE4381F2"/>
    <pav:lastSavedOn>2014-06-11 13:57:33 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2820E75B-959F-4C6A-8D67-AD9C22292B75"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:DADF2D2C-AA34-4339-B24C-5E885726DE31</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:05D03B82-E435-4E7C-9A43-AE9C7DF29A1F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:61625169-485B-48D0-9DBC-6D506383D7F8"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:47AA611C-52F9-451D-A32D-B74772D95E1D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <pav:createdOn>2014-06-11 13:57:32 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B82BB5C-552F-4359-8117-65E2C21FB4AC">
    <rdfs:label>Variant Frequency</rdfs:label>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DBE7CD7-EA07-4F4D-9250-FB8471CE8D1E">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8350EA7-C8A2-44AB-BE69-6B1844DC8076">
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:294D1B8B-6C69-42C3-B2E0-9A4F3FD352CC">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094">
    <permissions:permissions rdf:nodeID="N09ea8217d1164d4e80a272e711879f03"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:84DB5EC5-B980-4493-82E8-5E5D393FE2D9"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:47F5DF8D-6E93-4BEA-B0A0-65FBF75E4A01"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8272D2B6-0C9A-4ABA-B13E-74867D45B903"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:852C6E07-7D0F-4759-B60B-2F84975DE3EC"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2FB69F2-D2FF-43EF-8D5C-29732917A825"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:49E4005A-EE50-404F-A52D-3249F8464394"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A7D1991F-37FC-467F-8870-C6D9F2ED65ED"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:59B9FDA3-7951-46E5-B760-324B32029EC1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E2CE48A5-B949-4665-AEA2-11758EADAF68"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A7DD5680-2391-4EC5-A99C-AC221DB7CF67"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA9E42CC-F1E7-4CFD-AED6-F74E23CA07BD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3A6D6B4D-D206-4658-AF73-CF2B2F815A5B"/>
    <pav:createdOn>2014-06-01 20:21:30 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:7B7DC40D-1B3D-4BA0-BA38-41B9DA65EEF3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C2FB89B-001A-4C72-9EA0-3B9B45E12DA7"/>
    <pav:previousVersion>urn:domeoserver:annotationset:59A6F148-13BD-4552-BD4D-47BBA15E3627</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:A016E782-6083-4FAB-B5CD-6DA0BC2D96ED"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304642b062014642cf8be10000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BBE7FC4E-7040-47C6-BAAC-8D9809B16C22"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:3CE4DF44-922B-4B4F-9E0E-28118340C6C7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE66CAE4-E60C-4BCA-A279-D9DF438AEF11"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2A6302C7-8EF3-460C-B116-7E59FA9BE9DC"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629ce3c370001"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E87AF76A-CA84-48A5-9EAC-16029EFC79C1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BF9E7431-69B5-4BAE-A020-9DB51109BA3A"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:518D89E7-C4E7-42C6-A37E-48F86BA012B4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lastSavedOn>2014-06-02 11:54:54 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:928318F4-75B6-4942-841F-EEAC3724CEC6">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5AD7DDEE-BB3F-4435-8859-1FC48608C0DC">
    <sio:SIO_000111>(34068-7) DOSAGE AND ADMINISTRATION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34068-7) DOSAGE AND ADMINISTRATION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60B2FC2A-0FCD-47E1-8AF6-036903D2D8FE">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07689067-83B2-4A59-B4F7-83DFCFA0ED5D">
    <poc:Comment>positive or unknown = 2 annotations</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D811D5CC-451D-4E8E-9447-9B6228329CAC">
    <poc:MedicalCondition>death, respiratory depression, extreme sleepiness, confusion, shallow breathing, tonsillectomy, adenoidectomy, obstructive sleep apnea, </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CEA75987-4FBD-47E3-870C-867538E5366B">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35EE42D9-44F0-4D20-90F5-F737D9F13A26">
    <pav:previousVersion>urn:domeoserver:annotationset:DADF2D2C-AA34-4339-B24C-5E885726DE31</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:0E5C477A-C364-4B39-BD99-BF8BCFF13D7D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:lastSavedOn>2014-06-11 13:57:33 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0085D334-E933-4121-AA4D-45C85FA79976"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:290A03B7-2778-43B8-8B8B-4F4F7547BA6B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A3AAD6E7-A54A-4B2F-9829-90E41688953C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F3E7263-8583-4D92-9FAC-6592640CB6F1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9B9279C7-658C-406C-946D-9BFF5C459B06"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FAC3AAC8-B0C8-4681-A502-DAD45238EB0D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:EB38CF6C-6593-4ED5-BBC9-F6406EDC1134"/>
    <pav:createdOn>2014-06-11 13:43:01 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4999A1DA-C288-46D8-A62C-B991C9A4B2F7">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A6D6B4D-D206-4658-AF73-CF2B2F815A5B">
    <pav:lineageUri>urn:domeoserver:annotation:5AEDF9CC-43ED-4710-B590-4D225771E8D1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A3DC838-7F98-44F7-B8BE-DB357CB2F83F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:182124B1-5996-466F-858E-FC532C12BD72"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:68B513A5-D56D-4DF6-A372-20CB0B78A444"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B64B9D8-3BE7-46A5-99E8-51142C33754A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AB147F25-1B88-4069-9256-A953968F81BF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B0EBE3D-E880-49F6-AED2-BCC056A7B6BA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-01 20:57:33 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-06-01 21:05:20 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:801E4361-583C-4097-9F47-7910FDF70718"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4756A35-9B6E-41CC-BFA7-5E427BFBE0A7"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9e6e8b42d524426aa8c226118d1f12b3">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB5B085E-2C27-4F91-87B6-EDB4C719A149">
    <pav:lastSavedOn>2014-06-11 13:57:33 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-11 13:50:34 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD7A6545-5C8B-4FB2-A2ED-445623885F22"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:11FA8543-EFAE-41BB-AC14-B3FBE08DCAC3"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:2CE880A6-611C-44C6-A607-47BBCF65589F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5086E51F-BE9D-4B26-994F-F65D1039BDE2"/>
    <pav:previousVersion>urn:domeoserver:annotationset:DADF2D2C-AA34-4339-B24C-5E885726DE31</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:0E42F1FC-FFE7-441B-A855-F44B318EED2F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8757F043-1DF7-4DEA-8960-92BC05400D47"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:910AE070-EF69-4580-8FA8-D6AC65D9B23F"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:097E8AC0-79CD-44CA-BE54-2CC0BBF0008F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BBE7FC4E-7040-47C6-BAAC-8D9809B16C22">
    <ao:body rdf:resource="urn:linkedspls:uuid:10DE53A3-0606-4583-BA2D-25D07EA38D58"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3563965-B210-42C0-9FF0-A3486F2240E1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6A60543-E70E-4659-BE33-475B15815CF3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:44B83470-7A63-4402-A977-48C1847BDF4D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8ED8D02-7F93-41B5-908B-D5A8A907DF30"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F4BA538D-61A7-4EAD-8570-A3A806489044"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-02 11:23:15 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA82B2B8-D75E-48D2-805D-7373ECD081EA"/>
    <pav:lastSavedOn>2014-06-02 11:23:49 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:39C5C1E8-D80E-4CBB-99A0-4AB410862B09"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:1AC91D44-43AB-461A-BBAE-2DB0CE3D63A9</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D2F60DE8-DB29-4E1E-870B-8EBBD05CD648"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:040E1451-9494-4650-9EE0-23B7302B057A">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F9BC4EC-8268-4066-9F9B-7A3A397C25CF">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B38E1606-AC23-4903-9AB5-50032A302E19">
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95D272F9-EA2A-4E89-96A6-23E0A489EC62">
    <pav:lastSavedOn>2014-06-11 13:29:53 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9EE5574C-5B47-4322-8BF3-62AB4B50ED0B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DCCE915-58E2-43D0-8882-0D587754658C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:6BBC9479-F11A-4B2C-A0B5-80B1F2C47315"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:038C4F5D-424D-4EB6-AD1D-46B1168B4300"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F700493-AE5A-4434-A675-08B61AB15CC6"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2322D8A4-E687-416C-A663-2B4F6EB929F7</pav:previousVersion>
    <pav:createdOn>2014-06-11 13:15:08 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CB33E511-F9C4-44F5-89AA-B24118779113"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9DA5C585-5B84-4456-A50C-125561E7BB6A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A91AEB3D-420E-4C1B-8742-6E93D21FDF24"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:54CE33AC-544A-4F34-AE24-72F464099576"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:88C15D26-B0E7-4BA6-B4B5-711DC61447C0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B7DC40D-1B3D-4BA0-BA38-41B9DA65EEF3">
    <ao:context rdf:resource="urn:domeoclient:uuid:D4308DA5-4474-492B-AFCD-CFEE3F159D1C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C3AC9B3-D601-4136-A811-7C38BDF19C43"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6AF5971-80AE-4A6C-A511-F82D7494B773"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:075A7CA2-6401-4610-A335-F1E2AE43B9E0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D93C557-7BA6-4DCF-B075-71C884D5D59F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:E52D7AF5-8AC1-400C-B035-9C0F0E0306F6</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:781BBA63-F58B-4E56-AD8A-0062F37377E4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E7CA85B-4A8F-4CBE-8231-92F268786E9F"/>
    <pav:lastSavedOn>2014-06-01 20:50:40 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-01 20:31:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DB320B68-62FC-4457-B449-7E0CD9890D51"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-11 12:43:55 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629ce3c370001"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2524015E-FEBC-411E-BE2E-CD1735991ABE"/>
    <permissions:permissions rdf:nodeID="Naf54ad921c37440cacac3928dd3ff2e1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4BB2FDDE-C596-4CB9-8B7E-813073101762"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0EAF3C37-B91B-4D02-889E-1FAD55EA1307"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2C4A79FC-72E3-433A-9BE3-9ABDFE3AE46D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:13F6F038-D121-476D-B1F0-BC33B90EC49F"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9A46C3BE-6B69-4DEA-B2E1-10894DF16968"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:B6D4125E-A9ED-4C67-9E7E-F85511C24D3A"/>
    <pav:lastSavedOn>2014-06-11 14:13:31 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:5A8C6206-5882-423D-B3A3-28502F8548C3"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7B1DA8ED-BB80-4A6E-A9EB-9C126E1C6B49</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:35EE42D9-44F0-4D20-90F5-F737D9F13A26"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3655BA22-5D0B-4E5E-A3EF-FE724755AAE1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F87724F1-CAE8-41D2-96CC-D5D8903DABA1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:00356E6C-B77F-47B4-9089-E756E1C8F1CA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:B6BE3790-01FB-45A8-B8F9-338EAAC49441"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:691466C3-C16B-4654-9676-C6ABADBA26D8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3BD9A39D-8687-493B-8A92-3ABF36E8DCE1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DBD4128C-C218-48F8-BFBF-7A78F47CA224"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:53A083C1-5A46-42BC-9F87-EDA438AC8890"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DB5B085E-2C27-4F91-87B6-EDB4C719A149"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CB6A205D-3B24-4ACE-BA36-840F37E96BB0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ADF704DF-FD54-4F7D-8FA6-AD2051EF604A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:61CAAFE5-A2B0-401D-93DE-54BA4A2A05A4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:085DCEC8-3AA0-4DF0-8132-C06E95CFC077"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:95D272F9-EA2A-4E89-96A6-23E0A489EC62"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:11C2975B-D670-4D58-BE05-9895521B1515">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:F402EF1E-1334-42ED-A999-EE7766099656"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DEBF1763-8E56-4EA1-AEAF-BBCA6E565663"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-08-04 13:30:38 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5486F7DE-A8BF-4A3F-B93C-84D5BCD1F383</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:B8FA7095-4EDB-4DF4-9EAC-A4BEACE8D15F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F39A73F6-352B-45D8-93F4-B75B7DAE8DCA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA5BC6C6-51FF-46CE-ADC1-5C02EC5D7723"/>
    <pav:lastSavedOn>2014-08-04 13:30:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A04E56DA-84EB-468F-A39D-5ED23FC1F1A3"/>
    <pav:lineageUri>urn:domeoserver:annotationset:F3B6752D-AE4D-49AD-A013-9C25E53B3BD7</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C11BE719-29B5-4CB0-8D19-154841DA98A7"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A1663ECC-3221-459B-8FD0-69374505D314"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2DE75673-3411-4788-8A96-BA7CD4384E5B">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF9E7431-69B5-4BAE-A020-9DB51109BA3A">
    <ao:body rdf:resource="urn:linkedspls:uuid:E495D799-FBD4-414C-B469-19EB5A801B2C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:21BD891C-1A7D-4254-B84D-F08896010FBE"/>
    <pav:createdOn>2014-06-02 11:30:34 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B6734B02-ECA2-4C72-BF40-9F8C068486B0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:056DFCFD-7A3D-456D-BD1C-B5E0D7699D95"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B82BB5C-552F-4359-8117-65E2C21FB4AC"/>
    <pav:previousVersion>urn:domeoserver:annotationset:A2165F85-DA12-4AC2-A372-6EBD213B5987</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:72BD3694-98FC-40F3-B2A3-1555044DD90D"/>
    <pav:lastSavedOn>2014-06-02 11:34:25 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8650AFA8-B61A-4A92-A987-B371590DFBCE"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F40AD074-2E47-4331-866A-6D66E6A1356B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:8AB6F307-87A7-4718-8807-327A89AC39E4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ECF411C7-5E58-4EB7-ABF0-33EEE5C22D04"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53A083C1-5A46-42BC-9F87-EDA438AC8890">
    <ao:body rdf:resource="urn:linkedspls:uuid:7D046B8D-B703-41C7-8517-71383B7A565A"/>
    <pav:lastSavedOn>2014-06-11 13:57:33 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EBD286B2-69F4-4FD8-B7B2-6FED02812F9B"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:6B921A85-20B2-4EDF-B5A3-FAC50B718748"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:8767FAB4-E332-486A-BF44-4F093B1A29F5"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:ECF61358-2130-4306-BADA-B48E5133540C"/>
    <pav:createdOn>2014-06-11 13:38:35 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:DADF2D2C-AA34-4339-B24C-5E885726DE31</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:165E829E-984A-494F-8AB3-893041E5DEFC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A7FEED2-54CF-46CF-805B-6B2CBE0A39E2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:3F2F6001-FAD9-4998-BE98-36775E86BB95"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F40AD074-2E47-4331-866A-6D66E6A1356B">
    <pav:createdOn>2014-06-02 11:30:34 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F40AD074-2E47-4331-866A-6D66E6A1356B"/>
    <ao:exact>The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) conducted worldwide overviews of systemic adjuvant therapy for early breast cancer in 1985, 1990, and again in 1995. In 1998, 10 year outcome data were reported for 36,689 women in 55 randomized trials of adjuvant tamoxifen using doses of 20 to 40 mg/day for 1 to 5+ years. Twenty-five percent of patients received one year or less of trial treatment, 52% received 2 years, and 23% received about 5 years. Forty-eight percent of tumors were estrogen receptor (ER) positive (&gt; 10 fmol/mg), 21% were ER poor (&lt; 10 fmol/l), and 31% were ER unknown. Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone. Among these patients, 54% had node-positive disease and 46% had node-negative disease.\nAmong women with ER positive or unknown breast cancer and positive nodes who received about 5 years of treatment, overall survival at 10 years was 61.4% for tamoxifen vs. 50.5% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 59.7% for tamoxifen vs. 44.5% for control (logrank 2p &lt; 0.00001). Among women with ER positive or unknown breast cancer and negative nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p &lt; 0.00001).\nThe effect of the scheduled duration of tamoxifen may be described as follows. In women with ER positive or unknown breast cancer receiving 1 year or less, 2 years or about 5 years of tamoxifen, the proportional reductions in mortality were 12%, 17% and 26%, respectively (trend significant at 2p &lt; 0.003). The corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend significant at 2p &lt; 0.00001).\nBenefit is less clear for women with ER poor breast cancer in whom the proportional reduction in recurrence was 10% (2p = 0.007) for all durations taken together, or 9% (2p = 0.02) if contralateral breast cancers are excluded. The corresponding reduction in mortality was 6% (NS). The effects of about 5 years of tamoxifen on recurrence and mortality were similar regardless of age and concurrent chemotherapy. There was no indication that doses greater than 20 mg per day were more effective.</ao:exact>
    <domeo:uuid>F40AD074-2E47-4331-866A-6D66E6A1356B</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9AEA6CA0-21FB-4717-8052-914DBC2AEE4F">
    <ncit:Alleles>CYP2C9*1, CYP2C9*3</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3DC3EFBE-E013-4100-9C6D-51D5D6DC4B0F">
    <ao:body rdf:resource="urn:linkedspls:uuid:3E227EEC-8D40-41F8-9B19-35BA0F58C52B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:6FA1B68E-82C9-4FFF-943B-08856C6834BF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2BCE2A5B-B080-4BF0-8C54-6DEC6EEE09D8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0EB463AE-2287-43F0-8DA1-DD1C572AC24D</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:6556E663-F80F-43E2-A71E-4CAD11EF29B0"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C014A5BD-94D4-4BDC-8DE1-11AC0D8384FD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:105FB6F1-709B-4409-B416-BAF13AAAAFE4"/>
    <pav:createdOn>2014-08-02 11:09:07 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:6027D030-C83D-4E09-8DEB-BD62561A0E82</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:B09D63AD-3AC4-4D2E-936A-C37544BC26B5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:EE812AE1-C75A-4512-A501-E26A3E4C1E40</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF0C66C0-7137-472E-BF75-5A95C688E1F2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:68F2DD63-C330-4CA1-BB91-2D3A45E15087"/>
    <pav:lastSavedOn>2014-08-02 11:09:13 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CAC3933D-809D-4D96-8DCB-B56002C53C71">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6131A582-34D6-47BE-A4E5-C616495886DB">
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB39EC49-39E7-4F01-BDFA-DBB2A633035D">
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:38B40CF7-C8FF-4523-8FCC-9DD4D66AD8E0">
    <permissions:permissions rdf:nodeID="N8f6d72116c5b4af79c00733275d1f264"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:25AB90AC-C771-4406-977E-8DC2CA3E5DBE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:668B908C-47F9-41AA-BBFC-1B1DF64553E6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:50D1081C-CDDB-4751-AE94-76783A520183"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2014-06-01 18:18:53 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdOn>2014-06-01 15:26:15 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:870EBE5A-B94A-49FD-8FE1-0F574B19DB48"/>
    <pav:previousVersion>urn:domeoserver:annotationset:61A86E0B-6C37-411C-BF5F-7E2D47E73B76</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629ce3c370001"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7EB7FC17-7B01-48B4-9C16-A1ED65435E06"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A1BDAC9B-609B-4C7E-B58C-1EBA49888DA8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:938EE41D-651C-41ED-8C34-DD86053E22CF"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:5FD6BB9F-D38A-4E21-A7F7-F53FB5B3CE93"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D6A95D34-55A1-472A-A095-901E6BA00830</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:72F5818D-704A-4D56-AAD9-5D5D51E6E7F8">
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-monitoring-strategy</poc:MonitoringRecommendation>
    <dct:description>A strategy changed monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Change monitoring strategy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D4679C4-24B9-4A12-AE7A-6EF360A93822">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CB33E511-F9C4-44F5-89AA-B24118779113">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5CD1AE27-AFD2-4F5F-BF55-2EE63DF53514">
    <pav:createdOn>2014-06-01 20:12:29 -0400</pav:createdOn>
    <ao:suffix> (1.1)Extended adjuvant treatm</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>5CD1AE27-AFD2-4F5F-BF55-2EE63DF53514</domeo:uuid>
    <ao:exact>Letrozole tablet is an aromatase inhibitor indicated for:Â \nAdjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5CD1AE27-AFD2-4F5F-BF55-2EE63DF53514"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C2088FA5-4C4B-4269-BE84-0CBECDFB6D49">
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D032294E-CED1-410A-B8D7-381F84967E05">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Breast Cancer
Age
Women</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE66CAE4-E60C-4BCA-A279-D9DF438AEF11">
    <ao:body rdf:resource="urn:linkedspls:uuid:B30E27C7-9FC2-49F9-8322-0F737014ACC2"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-02 11:47:08 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB5A86FB-B345-4E1A-8900-8DEEEA090BF2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA1A5436-6353-49E0-B158-D24D32105570"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:698DED5B-0966-49DB-A5A0-88E02DBD1E0B"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:640C2180-199F-4CE7-9036-107C9B01972B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F9F0CCA-B6E8-41D6-84C8-186912D7E20B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:43BE40DF-E3A1-4B18-861F-5F151D1E6E92</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8A08744-2AEE-46C6-95C7-7CD50737E7F4"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:624952BE-02FA-4DBB-A8F8-7C324A7D27AE"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-02 11:43:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E227EEC-8D40-41F8-9B19-35BA0F58C52B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE1C623C-2CC3-43AB-B533-3C6D3C2D63A1">
    <ao:exact>Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-11 13:59:16 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FE1C623C-2CC3-43AB-B533-3C6D3C2D63A1"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>). </ao:prefix>
    <domeo:uuid>FE1C623C-2CC3-43AB-B533-3C6D3C2D63A1</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4DA68686-16C0-452D-A86A-A699696AE167">
    <ao:body rdf:resource="urn:linkedspls:uuid:34A768A9-B8F5-48A2-BAC4-BA33BBFEB0D8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A645FD45-0632-43FA-998C-381B1EA9E76D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:89485073-562F-4DAB-B1DF-419C02ACA2B8"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0EB463AE-2287-43F0-8DA1-DD1C572AC24D</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E05A092-48FB-442A-A294-377B4591CEBA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:25DA647B-FA49-4F68-92F1-7B4508C1AD2A"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5060AA2F-563F-4BDB-839A-F3162FF7EA14"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-08-02 10:57:29 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:1189C85F-D642-43D3-8F2D-A1796624A506"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:createdOn>2014-08-02 10:54:33 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:EE812AE1-C75A-4512-A501-E26A3E4C1E40</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F624380-C986-4568-BBAB-3023EC77F3E7">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F22F3EF-3DEC-46A7-8991-5011D63F1093">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:603D28B5-7467-45FC-88C4-58C305EE9549">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:603D28B5-7467-45FC-88C4-58C305EE9549"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-01 20:20:14 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:suffix>Â [see Clinical Studies (14.4, </ao:suffix>
    <ao:exact>Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>603D28B5-7467-45FC-88C4-58C305EE9549</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F97789E5-114B-431A-A577-9E031BDACDA4">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0804F2E0-3D85-4B4E-8C0E-77594705659F">
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-08-02 10:34:19 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9A0A7D04-0499-4BEC-88CB-133571A2B9AF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A2DE966A-0E58-4329-AC3F-EB75F66C6321"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5855F355-DEC4-4FB4-8E61-76248214F097"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:E0D86EDB-C3C6-4949-ADD3-3C324B912356"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3F4602EA-C765-49AF-BCD0-163D2C998E0D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:24704269-377D-49A6-8790-1E8DF7BCE2B1"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:099F3820-5DA9-4882-88DB-A3E01DF3B334</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:FFDA2233-33BA-4536-AF73-6526806736C1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-08-02 10:34:26 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:B4A46BE9-5408-46BA-9CC1-8B0430DC913D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:BE7C7835-7F73-4770-8C90-0BB58BE1F330"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D075A98A-6E8D-4058-8053-C50ED33E10AC">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71923767-C4E7-42DE-84F8-01605D56F151">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:71923767-C4E7-42DE-84F8-01605D56F151"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>71923767-C4E7-42DE-84F8-01605D56F151</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.</ao:exact>
    <pav:createdOn>2014-06-01 20:15:14 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F9F7D401-954A-4681-9DCF-4774DD0355CE">
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nefd281b91f734fb5983416885121f93d">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E817B0C6-D55A-458C-834F-E3108A61E647">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60B51941-6AAD-41C7-B336-A5DAEECDF8D3">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5CD3D25D-A767-4D5F-BBDC-A128401A7E65">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7520CD5-1D2F-4FE1-ACDB-BA5AF054911F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1483C104-1035-4F90-B6A1-E546F30356A4">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB5A86FB-B345-4E1A-8900-8DEEEA090BF2">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6FC4169-F8BF-4EA8-BC45-49CD447A8225">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:266752F2-12DA-4D05-A515-48ED6004FC91">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:EE8E5AB7-DFBA-4CD5-8C65-EF0F085A6F8B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMIPRAMINE-1827a5aa-733a-49d9-89d9-48ea0367b230.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:previousVersion>urn:domeoclient:uuid:B875CF2F-0A75-49DF-879B-C8BF82979A29</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:68BA1CEF-D530-4C64-9836-F6ACD01CE068"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629ce3c370001"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5E02AB2A-7ABF-4839-ABFD-6DEFF552645D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:A805FD4F-A44F-480F-A4FD-7BB2C11717E3</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <permissions:permissions rdf:nodeID="N9e6e8b42d524426aa8c226118d1f12b3"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2014-08-04 13:45:34 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-08-04 13:44:24 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E59B98C-D1FE-41D7-81D3-C3A9E7617BAD">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D0F83D6C-DD82-4333-BFF3-DE92D85685DC">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:FDF7BD4E-553F-4F43-9E6A-1BDDB1AE305A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:166E1275-A150-4DA6-9690-B18CDA86FA54"/>
    <pav:createdOn>2014-06-01 18:23:14 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304642b062014642cf8be10000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A1407863-3005-4220-AB14-446C3EC7B195"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:605401F9-CEC0-4386-9F96-10216E94DB09"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2A25A28C-E3A8-4E68-AE36-EFD658F4D76F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E008FAD-D62D-493D-800E-B4DB7F181625"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:D9A48574-7F84-4D1C-B3B1-C7F5BD271B81"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <permissions:permissions rdf:nodeID="Nbcc8ead230b2468bb617a5832941fc6f"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6C243EC9-2225-4772-9FAC-3D93C17E4CAF"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:35FB2E8E-AD51-4F49-993D-2C68F0FDE171"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7BFBC3AC-D8B5-415E-AB79-C58932414E1C"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:4034F2D7-4D06-41F3-8D94-F04B5C5F898E</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:78BB6A54-2C48-44AF-BC4F-5130336B0B4A"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629ce3c370001"/>
    <pav:lastSavedOn>2014-06-01 20:37:20 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB698F46-FE25-4759-8C5B-29163BA02518">
    <pav:createdOn>2014-06-01 18:07:18 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>AB698F46-FE25-4759-8C5B-29163BA02518</domeo:uuid>
    <ao:exact> In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeineâs active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB698F46-FE25-4759-8C5B-29163BA02518"/>
    <ao:prefix>Codeine is secreted into human milk.</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C665A2A-70BA-4895-9351-8CB339A59707">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-01 18:18:53 -0400</pav:createdOn>
    <domeo:uuid>8C665A2A-70BA-4895-9351-8CB339A59707</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8C665A2A-70BA-4895-9351-8CB339A59707"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Advise patients that nursing mothers taking codeine can have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix>. Advise nursing mothers to watch for signs of morphine toxicity in their infants which includes increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to the babyâs doctor </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:26FC75F4-DD53-4BA3-BAE1-B9F1BF18603C">
    <sio:SIO_000111>(68498-5) PATIENT MEDICATION INFORMATION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(68498-5) PATIENT MEDICATION INFORMATION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A46C3BE-6B69-4DEA-B2E1-10894DF16968">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-11 14:11:03 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:93985C36-8602-4407-801B-79E9A717126E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:52BB9789-9B14-4A35-8B25-A6925CF15C47"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:297B4881-837D-4A9C-A301-0F3EBE07A00A"/>
    <pav:lineageUri>urn:domeoserver:annotation:C6413742-58B8-4F30-942B-A3E407B932F1</pav:lineageUri>
    <pav:lastSavedOn>2014-06-11 14:13:32 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:15D03460-6022-4774-8B2B-D0705EB99F05"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:817D0D50-B6C9-432D-AC7F-9F2A5208CBDA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E8A6E52-FD5A-424D-B3DC-0D2BEE977A6B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DBD7BCFB-6031-43D2-8343-63D8B87AB27B">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Use specific</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D22783C7-ABFC-4DA3-8A47-F388EB9CA645">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Letrozole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E87AF76A-CA84-48A5-9EAC-16029EFC79C1">
    <ao:body rdf:resource="urn:linkedspls:uuid:AF3691C6-184F-4B0B-A35B-2A7D10DECD85"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF247ADE-CEC1-4294-951B-E346EEFCF880"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:04514E5A-CC45-47DE-9281-2FBD57AC110F"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:7DD80216-E6DB-48BD-A9C1-D37C6D156E4F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:040E1451-9494-4650-9EE0-23B7302B057A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:07BDCF78-FF4E-4E7B-B35D-B720E7D377B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D37E1623-1515-4F6A-93D4-F3BD2BBC1DE1"/>
    <pav:createdOn>2014-06-02 11:50:09 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:C3FDE415-0F58-43EB-AACA-E9FBA23086DF</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-02 11:50:17 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:630171C7-516F-4D9F-AFE2-922953BD73B5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C2088FA5-4C4B-4269-BE84-0CBECDFB6D49"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3ED74D87-17C8-4371-908E-0ED43A8E305C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9DD28267-65FB-4736-98AA-42F22B2AF105">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B09D63AD-3AC4-4D2E-936A-C37544BC26B5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B09D63AD-3AC4-4D2E-936A-C37544BC26B5"/>
    <ao:exact>Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PHENYTOIN-8848de76-8d74-4620-bcc7-a86a596e5dd9.html</ao:hasSource>
    <pav:createdOn>2014-08-02 11:09:07 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>. Consideration should be given to avoiding phenytoin as an alternative for carbamazepine in patients positive for HLA-B*1502.</ao:suffix>
    <domeo:uuid>B09D63AD-3AC4-4D2E-936A-C37544BC26B5</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E9375FA9-EB77-4EFD-A836-7C6191A16725">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E9375FA9-EB77-4EFD-A836-7C6191A16725"/>
    <ao:suffix>. Codeine is contraindicated in children who undergo tonsillectomy and/or adenoidectomy. Advise caregivers of children receiving codeine for other reasons to monitor for signs of respiratory depression.</ao:suffix>
    <pav:createdOn>2014-06-01 18:15:49 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>E9375FA9-EB77-4EFD-A836-7C6191A16725</domeo:uuid>
    <ao:exact>Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people. Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not. These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing. Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F2AE4E6-A6F9-4246-ADB2-188722E20D2A">
    <ao:body rdf:resource="urn:linkedspls:uuid:E56C5CC1-71B9-4F01-89AF-DD55E656ECE6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1FE38B13-8404-4584-A556-793401619B3D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-08-02 10:45:06 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:765F61E9-DD3D-4283-9374-462AD82510CA"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:86568F1A-F3B6-40F9-9C20-026FE207CD45"/>
    <pav:lineageUri>urn:domeoserver:annotation:CCFEAA13-F10B-47EA-B011-17E0DD13929D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA9237D5-68E7-4218-9215-072A32A7DD0C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:2CE4D16B-9B9B-4D0E-BBC4-6DC2E11BE320"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB722835-42BD-4854-8617-167FC619CE9D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:824A4432-39BC-49ED-8538-4C4DF2FFF7E9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:099F3820-5DA9-4882-88DB-A3E01DF3B334</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-08-02 10:45:00 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:01C992FE-311C-4E00-AA6C-D5D9E37D6718">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>ESR1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C1A7B574-6E7C-4642-82EC-465847EBE679">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9B2E784-E7B7-4BE7-9644-C8BAC52301DD">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5855F355-DEC4-4FB4-8E61-76248214F097">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3012</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>DPYD</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55A6159B-E8C0-4B22-AC5D-B84C70A50FE4">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B9EE241-FC5B-4C7D-AC32-CAB595297416">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMIPRAMINE-1827a5aa-733a-49d9-89d9-48ea0367b230.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9B9EE241-FC5B-4C7D-AC32-CAB595297416"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>9B9EE241-FC5B-4C7D-AC32-CAB595297416</domeo:uuid>
    <pav:createdOn>2014-08-04 13:45:32 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:18C88D86-53DA-4CD6-A6D4-DFADB6C6362D">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A26E190-386D-487C-9204-1A9FF093B3BF">
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E140DE6F-DDD3-4D85-86B9-5A73C2EEB94C">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:98445AC0-FF07-47CA-9FFF-2E34EC3A186A">
    <dct:description>A strategy changed monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Change monitoring strategy</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-monitoring-strategy</poc:MonitoringRecommendation>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D45E220-3807-489B-B2BF-EC91BDA967CC">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>CYP3A4, CYP2A6, CYP2C19</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E008FAD-D62D-493D-800E-B4DB7F181625">
    <ao:body rdf:resource="urn:linkedspls:uuid:DF914CBA-27EE-4C33-A929-F5D51EED1623"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F1D72A7-73E0-4C9B-935C-5EDCCA2982ED"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-01 20:37:20 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:BED33609-E929-4486-9EAC-0B963C21CC8F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:99F398CF-DA8E-4ACF-A452-BAC543EA248C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B06CC265-F8E0-4C28-9939-880EF88A5101"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:1CC417AA-FE45-443C-BE17-296F63E9FEB7</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D45E220-3807-489B-B2BF-EC91BDA967CC"/>
    <pav:createdOn>2014-06-01 20:33:19 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:0FFD0391-8E1C-417F-B431-7442EDC03CC4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8923DAA5-8BAE-4218-879B-8E392505B724">
    <sio:SIO_000111>(34068-7) DOSAGE AND ADMINISTRATION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34068-7) DOSAGE AND ADMINISTRATION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N09ea8217d1164d4e80a272e711879f03">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68BA1CEF-D530-4C64-9836-F6ACD01CE068">
    <ao:body rdf:resource="urn:linkedspls:uuid:66C8E7B7-9098-4C5B-9CE9-3A7593AD36C5"/>
    <pav:lastSavedOn>2014-08-04 13:45:34 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:C13D5842-56C3-4010-93F0-30E5F072C427</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:88018830-0B5D-482E-8031-2EC6F411DB72"/>
    <pav:createdOn>2014-08-04 13:45:32 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9B9EE241-FC5B-4C7D-AC32-CAB595297416"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:381FDCEA-10CB-4947-87D0-FE1B7B9AF309"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B80F8EAB-7286-4F17-A56E-99B9BCB60FAC"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE8E5AB7-DFBA-4CD5-8C65-EF0F085A6F8B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:C355731A-4AB5-43C2-80F9-CBFB4F23B03D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:753AA500-D0F4-4E93-B6AA-97DAFC61A156"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5C948C2D-1365-4583-BD08-43BAEFE60CC2"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78BB6A54-2C48-44AF-BC4F-5130336B0B4A">
    <pav:lastSavedOn>2014-06-01 18:43:12 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D0F83D6C-DD82-4333-BFF3-DE92D85685DC"/>
    <pav:createdOn>2014-06-01 18:43:11 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DBC567B-06FC-4E32-AF97-1F12BA46DF14"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0672652F-D2D6-4850-B292-41777DDD93A4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:77FA206B-E97B-4DB2-95C8-2CAEE18D73ED"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9DD28267-65FB-4736-98AA-42F22B2AF105"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C4FF148F-DA8E-460A-9416-12EABD3C0787"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A76CAD7-6AFA-4C1E-AFDD-B56F1FA2AD22"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A4A4214A-FDFF-4CBD-87E9-A1016E1FC8C8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC33EDAA-A35F-4D88-97E0-9634AF0206AD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3A1AA6C-1963-4703-920E-3BA4EA5D0089">
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7925A8BE-4401-4E13-A60C-0CFB0EFB7480">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EC560B3F-80E8-45DF-8C22-E3764D8A78E3">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3F4602EA-C765-49AF-BCD0-163D2C998E0D">
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Do not start</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7DD5680-2391-4EC5-A99C-AC221DB7CF67">
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:4693793C-A4BA-4B78-8FEF-0E9B1A3DCA6D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:7762E8FF-2F66-49F9-8F33-6361BE15F2B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8EA68AC5-1674-484B-B8D0-2AECA70B9FE8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A26E190-386D-487C-9204-1A9FF093B3BF"/>
    <pav:previousVersion>urn:domeoclient:uuid:E52D7AF5-8AC1-400C-B035-9C0F0E0306F6</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:275605A0-79AB-4D06-9E3C-B817A21D1490"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-01 20:50:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBF04D85-16FE-4392-BAA3-393C676C0B40"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:523071B4-7A9B-4843-94CE-574131C7DAB0"/>
    <pav:createdOn>2014-06-01 20:46:16 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1DCFD255-484A-4994-8EF6-3AA59A2BB3E5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(42232-9) PRECAUTIONS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(42232-9) PRECAUTIONS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6C33E7C-186A-48BB-9964-FC20E5A26AD1">
    <ao:suffix> (see CLINICAL PHARMACOLOGY:</ao:suffix>
    <ao:exact>Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses</ao:exact>
    <ao:prefix>) and long duration of warfarin therapy. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E6C33E7C-186A-48BB-9964-FC20E5A26AD1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E6C33E7C-186A-48BB-9964-FC20E5A26AD1"/>
    <pav:createdOn>2014-06-11 14:04:03 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:038C4F5D-424D-4EB6-AD1D-46B1168B4300">
    <sio:SIO_000111>(43682-4) PHARMACOKINETICS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43682-4) PHARMACOKINETICS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F5428A8-04B1-4598-99C2-43DB74E0B647">
    <poc:MedicalCondition>premenopausal 
oophorectomy 
ovarian irradiation
irradiation
metastatic breast cancer
breast cancer
cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:99B319B0-E8D9-4249-B5BB-364D474CC619">
    <ao:body rdf:resource="urn:linkedspls:uuid:91BC11CB-E58D-4B99-AEB6-CC21C25F4C4B"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:022EF4DB-AF0D-45EF-8063-1DF9D5727347"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:944E2306-B45C-43F2-9DD4-DBE4D03BAEFC"/>
    <pav:createdOn>2014-08-02 11:36:49 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:10A013FE-71ED-4FCE-AE89-B3DC27A94F8D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:507F466D-7AFA-483A-882D-799FA2A7E893</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8875C6FE-DBD8-404E-8B48-04D200BEEFF9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:995F0F62-7DDA-461A-B1F4-DB46B657ED85"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:99A8346F-0797-4D61-8489-57A101437F89"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:71A91CA4-9FE2-4D1B-812A-AD930632F0BA"/>
    <pav:lastSavedOn>2014-08-02 11:36:55 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:FA1B0720-4C45-455E-A357-D15F4385426A</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:309964A6-727A-4B76-9D79-9E7DCF57399A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A435508A-E2FE-45FB-9A4B-0CDD1F6028F1">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD7A6545-5C8B-4FB2-A2ED-445623885F22">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00D39640-85A6-4258-99D9-2F6F990A7699">
    <rdfs:label>Variant Frequency</rdfs:label>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A88FBF0-A260-4DEF-B583-5E9E8F918005">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:043A8FED-C2FF-4047-BA84-C4896E5062DA">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3BD9A39D-8687-493B-8A92-3ABF36E8DCE1">
    <pav:previousVersion>urn:domeoserver:annotationset:DADF2D2C-AA34-4339-B24C-5E885726DE31</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:678DD77E-B082-41EA-8854-DA985481EBB1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:CE087B1D-B7B6-43D4-80F5-1F284A6E2CFB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:25A004DF-00A0-434B-857D-AD64FE5F5005"/>
    <pav:lastSavedOn>2014-06-11 13:57:33 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4DD032C9-55D0-4331-9441-E2547D5E5816"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:16647501-DBAD-4E73-BB9F-26FCEC76D113"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AD380829-33F2-467D-8FFB-C5E8CBD01FF5"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA7853CA-D5EE-4BB9-BFBA-7B46AEDB5250"/>
    <pav:createdOn>2014-06-11 13:42:09 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC33EDAA-A35F-4D88-97E0-9634AF0206AD"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:AF8DB776-902D-4D64-B696-3FC851874FB8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A91AEB3D-420E-4C1B-8742-6E93D21FDF24">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0E5C477A-C364-4B39-BD99-BF8BCFF13D7D">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5BA002F2-35EE-4CE2-BCB7-FE83BF8FF7A5">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A18AC49-4F82-4AE2-B58C-9068D4CE2A8B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DB6B01C8-0B4A-4A1B-96FB-1F1C5B4D4BAB">
    <poc:MedicalCondition>breast cancer, postmenopausal</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:995F0F62-7DDA-461A-B1F4-DB46B657ED85">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:61CAAFE5-A2B0-401D-93DE-54BA4A2A05A4">
    <ao:body rdf:resource="urn:linkedspls:uuid:CC26B2F3-DCB0-45D7-AD56-ADA3439144E5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-06-11 12:45:43 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5EF2DA97-251F-4040-B369-991E5B94F590"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <pav:createdOn>2014-06-11 12:45:43 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F6CA925-F781-4E8B-82F4-1C65CA1F0915"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:548EFA8F-26D0-4768-A40E-4B8E244415B1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:57037122-268D-4AA1-8C43-C8CD323EDB8A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8C4E5F2-9109-4AC8-9FFD-1D78D4BE6D6B">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34090-1) CLINICAL PHARMACOLOGY</poc:productLabelSection>
    <sio:SIO_000111>(34090-1) CLINICAL PHARMACOLOGY</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D37E1623-1515-4F6A-93D4-F3BD2BBC1DE1">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:715FBAF4-B02C-4176-9F1B-0A9DD25FB455">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EDE35E41-6B9A-4949-9334-3BA2C5FC0448">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2AF296C4-A33C-48D1-A5AE-B53A4462F7E5">
    <sio:SIO_000111>(43682-4) PHARMACOKINETICS</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43682-4) PHARMACOKINETICS</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFB0DE82-88B3-430F-8DC0-AD9A266DFEC0">
    <ao:suffix> Subjects who are heterozygous extensive metabolizers have, on average, 2-fold higher voriconazole exposure than their homozygous extensive metabolizer counterparts</ao:suffix>
    <domeo:uuid>CFB0DE82-88B3-430F-8DC0-AD9A266DFEC0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CFB0DE82-88B3-430F-8DC0-AD9A266DFEC0"/>
    <ao:prefix> </ao:prefix>
    <ao:exact>Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolizers have, on average, 4-fold higher voriconazole exposure (AUCÏ) than their homozygous extensive metabolizer counterparts.</ao:exact>
    <pav:createdOn>2014-08-02 11:31:49 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/VORICONAZOLE-ce3ef5cf-3087-4d92-9d94-9eb8287228db.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8642430-877D-4F0B-8ED2-032AF7428A76">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34078-6) NURSING MOTHERS</poc:productLabelSection>
    <sio:SIO_000111>(34078-6) NURSING MOTHERS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FDF7BD4E-553F-4F43-9E6A-1BDDB1AE305A">
    <pav:createdOn>2014-06-01 18:44:56 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:55CB7EF8-A6B6-4D3F-9A7F-DCF6A7E08FE4"/>
    <pav:lastSavedOn>2014-06-01 18:56:28 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DB6B01C8-0B4A-4A1B-96FB-1F1C5B4D4BAB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D22783C7-ABFC-4DA3-8A47-F388EB9CA645"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9FBD8FD1-24C2-473F-A864-16F7B7D1D3F9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:9D12DEFB-A7A6-432B-A02F-A226BC80460F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:241AC904-E593-4A48-9E32-7846142BF6D0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:12247663-6D8E-4333-8FCA-0EC431436874"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:3146B9AA-68A2-4E19-91D9-D0AC98F6AC7C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CFA9A1B1-F6CA-4A27-A169-261051BF3E8A"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F0FFB28-D438-4B2B-BE87-A1AD3D082C02">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e14304642b062014642cf8be10000">
    <foafx:email>acockerham01@gmail.com</foafx:email>
    <foafx:name>Alex</foafx:name>
    <foafx:middlename></foafx:middlename>
    <foafx:lastname>Cockerham</foafx:lastname>
    <foafx:title></foafx:title>
    <rdfs:label>Alex</rdfs:label>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:homepage></foafx:homepage>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:firstname>Alex</foafx:firstname>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:49ACD5A8-48E7-4C4E-A4B9-DAF372EB24DC">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1663ECC-3221-459B-8FD0-69374505D314">
    <domeo:uuid>A1663ECC-3221-459B-8FD0-69374505D314</domeo:uuid>
    <pav:createdOn>2014-08-04 13:30:38 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A1663ECC-3221-459B-8FD0-69374505D314"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOMPIRAMINE-4074b555-7635-41a9-809d-fae3b3610059.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8</ao:suffix>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called âpoor metabolizersâ); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6D4125E-A9ED-4C67-9E7E-F85511C24D3A">
    <ao:body rdf:resource="urn:linkedspls:uuid:FE997C42-A3EA-417B-AB18-79D16C65178F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DB2EAE02-3287-49AA-9FDB-D44A830B56BF"/>
    <pav:lastSavedOn>2014-06-11 13:35:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:60B51941-6AAD-41C7-B336-A5DAEECDF8D3"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F9F5F59-7754-4F91-9B42-F5BE5C8ADAD8"/>
    <pav:previousVersion>urn:domeoserver:annotationset:544466F7-3BAA-402F-8D8F-EAB6AA612F2E</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:4692FB98-A64C-40B7-B39D-39E13B9E1BD1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:2936B938-6AC4-43F5-BFC2-4E299D5E7DA8"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE7B9DF8-FB55-40CF-8FDC-9314444F8486"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9AEA6CA0-21FB-4717-8052-914DBC2AEE4F"/>
    <pav:createdOn>2014-06-11 13:35:02 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D36764F-323E-47A6-B290-5C391ADD84BA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ECF61358-2130-4306-BADA-B48E5133540C">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <rdfs:label>VKORC1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DED2EDC8-D32C-4BEC-B3D0-8F766D1566B4">
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63CB3359-94D1-40EE-AF4F-853814B8E2BE">
    <ao:suffix>Â [see Clinical Studies (14.4, 1</ao:suffix>
    <ao:exact>Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:63CB3359-94D1-40EE-AF4F-853814B8E2BE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>63CB3359-94D1-40EE-AF4F-853814B8E2BE</domeo:uuid>
    <pav:createdOn>2014-06-01 20:17:53 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:61A57170-940C-49B8-8EAE-7336CF202D8E">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B667F421-8E8F-44D2-9A57-4CC1AEDC2893">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F87724F1-CAE8-41D2-96CC-D5D8903DABA1">
    <pav:lastSavedOn>2014-06-11 14:13:32 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8923DAA5-8BAE-4218-879B-8E392505B724"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A9360526-75C3-4E43-A4ED-13FB7F93DB8B"/>
    <pav:createdOn>2014-06-11 14:11:30 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F624380-C986-4568-BBAB-3023EC77F3E7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:2E3A1259-11DD-4FCD-BF11-637CD6DA478B</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:DBD7BCFB-6031-43D2-8343-63D8B87AB27B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EAA417CF-C05A-4863-A358-42D28D8EC5FC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2FE5A7C6-CC4D-4D04-882A-AF096D8A4799"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E099BC1-7905-4F64-8057-156FC53ADB58">
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:5486F7DE-A8BF-4A3F-B93C-84D5BCD1F383">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-08-04 13:31:50 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629ce3c370001"/>
    <pav:lineageUri>urn:domeoserver:annotationset:F3B6752D-AE4D-49AD-A013-9C25E53B3BD7</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="Nde51ee3ee1974e839ee60f86a861636f"/>
    <pav:createdOn>2014-08-04 13:29:56 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOMPIRAMINE-4074b555-7635-41a9-809d-fae3b3610059.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:8C79C7D5-64C2-45DF-8C42-86AFF653590C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:11C2975B-D670-4D58-BE05-9895521B1515"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>urn:domeoclient:uuid:FD81232D-0EA5-4BAC-AF5F-6B7685FD39DB</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99F398CF-DA8E-4ACF-A452-BAC543EA248C">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A016E782-6083-4FAB-B5CD-6DA0BC2D96ED">
    <ao:body rdf:resource="urn:linkedspls:uuid:468FE543-AD1E-48C2-AEC2-929DA27DC15F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:E52D7AF5-8AC1-400C-B035-9C0F0E0306F6</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:53F71014-8A27-4415-B21D-AFF704D17012"/>
    <pav:lastSavedOn>2014-06-01 20:50:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:23B5DEBF-032B-44AD-86B6-0A5665A87474"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8350EA7-C8A2-44AB-BE69-6B1844DC8076"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9631DAFD-657D-4B15-B45C-6749370AB9DC"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-01 20:29:42 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2B19285-CDA5-4F48-BD66-9F40377683C6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3219E3B4-644F-4DCE-8741-7846947834CD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3FC2FDC3-15E8-4CB3-8CA4-01B7647070B0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:CDA25E4F-5AD6-49AC-BFDC-FB737EF18E43"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21F0DD09-9A9B-44AA-B511-DECE65073BED">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7792C95F-0D5A-4A19-913A-CFD050D291C3">
    <pav:createdOn>2014-06-11 13:36:21 -0400</pav:createdOn>
    <ao:suffix>.4</ao:suffix>
    <domeo:uuid>7792C95F-0D5A-4A19-913A-CFD050D291C3</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In an observational study, the risk of achieving INR &gt;3 during the first 3 weeks of warfarin therapy was determined in 219 Swedish patients retrospectively grouped by CYP2C9 genotype. The relative risk of over anticoagulation as measured by INR &gt;3 during the first 2 weeks of therapy was approximately doubled for those patients classified as *2 or *3 compared to patients who were homozygous for the *1 allele</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7792C95F-0D5A-4A19-913A-CFD050D291C3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0838B265-A37E-4346-BF96-4C054DFB84AD">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0236F550-A39D-490D-B4BD-21E191A6AD30">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BCFB7B91-25DB-40CF-A05D-7A83778BB16D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0E42F1FC-FFE7-441B-A855-F44B318EED2F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06E2B901-88BC-4FE4-878C-CDD6CF4D6B0E">
    <domeo:uuid>06E2B901-88BC-4FE4-878C-CDD6CF4D6B0E</domeo:uuid>
    <ao:prefix>.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-08-02 11:20:18 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PHENYTOIN-8848de76-8d74-4620-bcc7-a86a596e5dd9.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:06E2B901-88BC-4FE4-878C-CDD6CF4D6B0E"/>
    <ao:exact> Consideration should be given to avoiding phenytoin as an alternative for carbamazepine in patients positive for HLA-B*1502.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C5288E1E-A5A7-443D-9D68-3557A9B8EC13">
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>C5288E1E-A5A7-443D-9D68-3557A9B8EC13</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C5288E1E-A5A7-443D-9D68-3557A9B8EC13"/>
    <pav:createdOn>2014-06-11 13:32:05 -0400</pav:createdOn>
    <ao:exact>A meta-analysis of 9 qualified studies including 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>. Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. For patients carrying at least one copy of the CYP2C9*3 allele, t</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E1DED8FC-F1B0-4719-B4F7-E38CF857E3CE">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94ADE34C-D689-4935-81C9-D5C7435911A2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>postmenopausal, breast cancer</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B1138F44-9FEE-4242-8404-881C86C069D3">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:10A013FE-71ED-4FCE-AE89-B3DC27A94F8D">
    <rdfs:label>Voriconazole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00582</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E7CA85B-4A8F-4CBE-8231-92F268786E9F">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:62F162C4-135E-4C80-90D5-5AE8570228F2">
    <rdfs:label>BRAF</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000004801</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F7CD8925-D7A3-41BD-B804-02AAEAF23F8A">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F1D72A7-73E0-4C9B-935C-5EDCCA2982ED">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>pk and pd impact implicated
more than  one annotation possible
no clinical condition related effect
dose indicate concomitatn med concern of above CYPs
metabolite activity unknown
clinical trial information?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B615F670-F9AA-4781-B6AF-57B8D5543BAD">
    <ao:exact>Respiratory depression and death have occurred in children who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] or high morphine concentrations). Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-06-01 17:59:14 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B615F670-F9AA-4781-B6AF-57B8D5543BAD"/>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>B615F670-F9AA-4781-B6AF-57B8D5543BAD</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91D240AB-DFAF-4F14-BE22-B6B70925677A">
    <poc:MedicalCondition>liver disease</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34A768A9-B8F5-48A2-BAC4-BA33BBFEB0D8">
    <rdfs:label>Recommended</rdfs:label>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91BC11CB-E58D-4B99-AEB6-CC21C25F4C4B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>how should we annotate this comparison? should we treat it as just being heterozygous positive? if so how do we indicate what the baseline it is being compared to?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9B9EF819-9039-486A-8EF5-D8EE4586786F">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <rdfs:label>VKORC1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3146B9AA-68A2-4E19-91D9-D0AC98F6AC7C">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F380EF82-7B06-4628-B23B-75D9C7B7337E">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EB7FC17-7B01-48B4-9C16-A1ED65435E06">
    <ao:body rdf:resource="urn:linkedspls:uuid:02D85B22-A258-4FF9-89AB-216AC9D5DDA9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:BBE9B27F-7731-4E0A-9729-BA2B9CE568DF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-01 18:10:46 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:D6A95D34-55A1-472A-A095-901E6BA00830</pav:lineageUri>
    <pav:lastSavedOn>2014-06-01 18:10:47 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB840164-D8F6-43AA-AD61-610E276C8003"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E932C75-BC6C-4269-AE1B-871FF55D1BFD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:38B40CF7-C8FF-4523-8FCC-9DD4D66AD8E0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9271B114-3F36-4AF9-8EE0-D60F5AB36CD2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EACA5F51-F689-4BD5-9065-802E3BB0555A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:703F1D22-FED4-4E58-9216-96D1492AB9EE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0ACBA9FB-1386-45B7-A361-3F22E768F627"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0245F231-BF84-4799-9D5F-88730A3415D9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:95C516F2-F188-48A9-AA27-93B80D64DEBF"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1C340683-6435-4DF4-95F9-ABF7890994C6"/>
    <pav:previousVersion>urn:domeoserver:annotationset:06189207-4913-468A-870F-4CE1019539BA</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4EECF41-92BE-4099-9881-B076F4CAE1D8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6BE3790-01FB-45A8-B8F9-338EAAC49441">
    <ao:body rdf:resource="urn:linkedspls:uuid:C37F4081-3C3E-4077-ADE2-6E2ED9FE4353"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0388B3EC-40C4-447D-9172-3E925C19BB6A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:98445AC0-FF07-47CA-9FFF-2E34EC3A186A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:3508FAF5-3249-49A0-AE93-B0E0A6BED3DC</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:D075E9C9-B7BD-48C6-8355-DD2C9A3FCA33"/>
    <pav:createdOn>2014-06-11 14:04:03 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A83D4B39-1BC1-4311-9DC6-45C82270D3D9"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-11 14:04:04 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:3FB4857C-421D-40CB-ADB0-1EB479BFE4AB"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E6C33E7C-186A-48BB-9964-FC20E5A26AD1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D4B6D211-BD6A-4A30-AC82-12687AEDE502"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F380EF82-7B06-4628-B23B-75D9C7B7337E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25DBAF85-B124-422C-A1DD-13CA32E00C26">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CEF2E37B-C0A4-4F4B-A2A8-38BEC4B8DD44">
    <pav:createdOn>2014-06-02 11:33:05 -0400</pav:createdOn>
    <domeo:uuid>CEF2E37B-C0A4-4F4B-A2A8-38BEC4B8DD44</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>In the Hubay study, tamoxifen was added to "low-dose" CMF (cyclophosphamide, methotrexate and fluorouracil). In the NSABP B-09 study, tamoxifen was added to melphalan [L-phenylalanine mustard (P)] and fluorouracil (F). </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CEF2E37B-C0A4-4F4B-A2A8-38BEC4B8DD44"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit. In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77163E48-FDB2-4C0A-A127-B74C2095634E">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2070AEB-1F92-495D-B89F-7C4754BFDE8D">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15AE862E-E584-4B3B-9944-03091896D9D3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:13A9663E-FDF9-4AF9-94C4-DFCC2515F45C">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ED1438B9-484C-417F-81FC-9615F534707B">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6AF5971-80AE-4A6C-A511-F82D7494B773">
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA789C7F-D6A1-414F-BC74-A37C3C396513">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8AB6F307-87A7-4718-8807-327A89AC39E4">
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:730E95BC-4718-48A0-9740-1B5D55D77A40">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE360A0D-A297-40DC-936D-5F5D1222846C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <rdfs:label>VKORC1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6B921A85-20B2-4EDF-B5A3-FAC50B718748">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6B921A85-20B2-4EDF-B5A3-FAC50B718748"/>
    <pav:createdOn>2014-06-11 13:38:35 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin</ao:exact>
    <domeo:uuid>6B921A85-20B2-4EDF-B5A3-FAC50B718748</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gen</ao:suffix>
    <ao:prefix>Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle, through inhibition of vitamin K epoxide reductase (VKOR), a multiprotein enzyme complex. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C37F4081-3C3E-4077-ADE2-6E2ED9FE4353">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(42232-9) PRECAUTIONS</poc:productLabelSection>
    <sio:SIO_000111>(42232-9) PRECAUTIONS</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:678DD77E-B082-41EA-8854-DA985481EBB1">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <rdfs:label>VKORC1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:854159CB-9EDA-4075-8EA9-8582AC113366">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34090-1) CLINICAL PHARMACOLOGY</poc:productLabelSection>
    <sio:SIO_000111>(34090-1) CLINICAL PHARMACOLOGY</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86568F1A-F3B6-40F9-9C20-026FE207CD45">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <rdfs:label>Do not start</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA97D38E-6D70-4646-8118-00559556A4D4">
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdfs:label>Recommended</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB47130D-2050-4DE9-A0B7-7D893485F387">
    <ao:context rdf:resource="urn:domeoclient:uuid:CFB0DE82-88B3-430F-8DC0-AD9A266DFEC0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:159DE912-8E3E-4C8A-952C-5D56B03F4261"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:9DD21799-0F69-4930-B82C-B0D33F94C23C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5F57EB18-DEBF-48FA-BE9E-0343092EC802</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:C588CD5A-BCC0-4B89-B85B-C0C91E3D4EA1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F18267F5-8923-48E3-B45F-EAC7D10A80A8"/>
    <pav:lastSavedOn>2014-08-02 11:31:56 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-08-02 11:31:49 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA081AF8-B5DD-4E3F-8A59-4FFBAD50147B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A34B301-47EA-4BF6-B389-C650617368B8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:507F466D-7AFA-483A-882D-799FA2A7E893</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:09CFCA72-AD6C-45E3-A210-C2FDA3847192"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16175971-B5AE-48AB-9C1F-13487FB63F5F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0AF9E34D-BB35-4C4E-A120-D5B8F937F55A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>dehydrogenase (DPD) deficiency, stomatitis, diarrhea, neutropenia, neurotoxicity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15D03460-6022-4774-8B2B-D0705EB99F05">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Use specific</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:703F1D22-FED4-4E58-9216-96D1492AB9EE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:534AC637-5CB9-405F-89FB-37DE9E223EA1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9DD21799-0F69-4930-B82C-B0D33F94C23C">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36E46813-19B9-4E7A-B494-DC44E7E77A5C">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>CYP2C9*1/*1, CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3, CYP2C9*3/*3</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:14A4B8C7-A2F8-4432-9D84-03A047BA880A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>postmenopausal women
metastatic breast cancer
locally advanced breast cancer
breast cancer
cancer
antiestrogen therapy</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59B9FDA3-7951-46E5-B760-324B32029EC1">
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:B38E1606-AC23-4903-9AB5-50032A302E19"/>
    <pav:lastSavedOn>2014-06-01 20:50:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:E52D7AF5-8AC1-400C-B035-9C0F0E0306F6</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E3BC098-863B-4FD1-9E5F-F4C244D690CD"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6EE754B-3ACF-4D28-82B0-173F818815F2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:51D8AD88-84BD-499D-89B1-5A13D094E89B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:01C992FE-311C-4E00-AA6C-D5D9E37D6718"/>
    <pav:createdOn>2014-06-01 20:50:40 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1D33A037-01E3-4544-9149-0E57600DD51C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4756A35-9B6E-41CC-BFA7-5E427BFBE0A7">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44423DFB-386B-41D4-A5E8-35AB0C33FE19">
    <domeo:uuid>44423DFB-386B-41D4-A5E8-35AB0C33FE19</domeo:uuid>
    <pav:createdOn>2014-06-11 13:29:53 -0400</pav:createdOn>
    <ao:exact>188Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9 and *11 alleles in Caucasians</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:44423DFB-386B-41D4-A5E8-35AB0C33FE19"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:77D0D8B2-83A4-43B1-82A7-ABE5233A32EE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-01 21:05:18 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:77D0D8B2-83A4-43B1-82A7-ABE5233A32EE"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>â¢</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:exact>\nif tamoxifen citrate tablets lowers the chance of getting breast cancer in women who have abnormal breast cancer genes (BRCA1 and BRCA2)</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E525148-0789-4948-B85A-293C5034E5E3">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:40EA8DAC-237D-401C-ACD3-F0B22A66F340">
    <sio:SIO_000111>(42232-9) PRECAUTIONS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(42232-9) PRECAUTIONS</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8272D2B6-0C9A-4ABA-B13E-74867D45B903">
    <ao:body rdf:resource="urn:linkedspls:uuid:EAF55A68-F83C-4EA3-ACCE-A7D22C0D74A8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A448D700-3F1E-4D64-870C-505840A1EC4E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:D1378C98-3880-453B-8C8E-7C875F23A8C8"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1AC91D44-43AB-461A-BBAE-2DB0CE3D63A9</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-02 11:23:49 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8C4E5F2-9109-4AC8-9FFD-1D78D4BE6D6B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-02 11:20:27 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:2B858186-07FF-44BE-863D-05D40DD39D4F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C2FB89B-001A-4C72-9EA0-3B9B45E12DA7">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8613DBE-E23B-4505-97DC-D1A8904A9B30"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E80F8715-EB61-449E-A924-4D82E72F059E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:2E40CE4B-F0A4-4DD0-B730-62D6531EBDAF"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:6AA7F636-6F42-4B80-841F-F2B140D5A4DA"/>
    <pav:createdOn>2014-06-02 11:54:42 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:21EBE267-EA4C-4E5B-852A-115A464D4531</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:52659CB2-2836-4827-AA04-68D75C4A4B31"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-02 11:54:54 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA139D1F-5943-42B5-B46F-936534FF180D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E099BC1-7905-4F64-8057-156FC53ADB58"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2A02EB88-FB01-4216-A878-9EE08371A1E2"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:606F71C5-8ED6-4EA0-8F3A-1EFA695FBC76">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:61625169-485B-48D0-9DBC-6D506383D7F8">
    <rdfs:label>POLG</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:9179</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2CE48A5-B949-4665-AEA2-11758EADAF68">
    <ao:body rdf:resource="urn:linkedspls:uuid:EDE35E41-6B9A-4949-9334-3BA2C5FC0448"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:32C7D92F-8B7C-4FC1-BE72-43A4987726AC"/>
    <pav:createdOn>2014-06-01 20:41:40 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:742D9FCD-2D9A-468B-B1DE-2EA9C3786782"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB39EC49-39E7-4F01-BDFA-DBB2A633035D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:DFA36CF5-82DD-42C0-8AEC-980D7F409410"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-01 20:50:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:E52D7AF5-8AC1-400C-B035-9C0F0E0306F6</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:16175971-B5AE-48AB-9C1F-13487FB63F5F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B12F04A-876C-40C2-BD49-80D7A1174AE8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B46F04DC-85C8-4982-8ADB-7231FDAE4913"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D281CDBD-9057-40C6-9414-F16357D3042C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DBEB0ACB-D1CB-409F-8826-3D87E728DE4C">
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2ED739B4-0C5F-4523-B4E9-9392184D80A5">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:640C2180-199F-4CE7-9036-107C9B01972B">
    <domeo:uuid>640C2180-199F-4CE7-9036-107C9B01972B</domeo:uuid>
    <ao:prefix>re not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Healthcare Professionals can obtain a Gail Model Risk Assessment Tool by dialing Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX). </ao:prefix>
    <pav:createdOn>2014-06-02 11:43:12 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen in these patients.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:640C2180-199F-4CE7-9036-107C9B01972B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:71A91CA4-9FE2-4D1B-812A-AD930632F0BA">
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94D2C52A-7138-4F35-91ED-9246F840B00C">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:768262D8-96AB-41E7-9186-5A319FC41A28">
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB840164-D8F6-43AA-AD61-610E276C8003">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1DAE0D7E-358C-4CB1-8BFA-B6EE64B95E61">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43685-7) WARNINGS AND PRECAUTIONS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(43685-7) WARNINGS AND PRECAUTIONS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16729159-3AAD-4126-B53D-A07E34E336FE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA9BC8D1-0537-43CA-9563-9EE677C227D5"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-08-04 13:37:02 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:9075139C-C17E-487B-BDFB-2F87609BC9B9</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:15AE862E-E584-4B3B-9944-03091896D9D3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DC9DDD0-E979-4202-B695-57DAC5E82F5D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E9A7644-D20B-4E3E-BC6F-7B20E01712E0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:55A6159B-E8C0-4B22-AC5D-B84C70A50FE4"/>
    <pav:createdOn>2014-08-04 13:37:01 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:49957CE8-4BDB-49B5-899D-F9140D2F0B6B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FA23F89C-894F-406C-ACB1-E2C29861E5CA</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:923A77D4-C08D-44B0-862C-B0A9234FBFB9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA5CB1FD-D1F7-4527-A5EC-8F6AD26EDF25">
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E93E67E-7C76-44BE-AFE1-D5AE75C92344">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nea5bffa91b74453aa04555d7180f2802">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4308DA5-4474-492B-AFCD-CFEE3F159D1C">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> The effects of about 5 years of tamoxifen on recurrence and mortality were similar regardless of age and concurrent chemotherapy. There was no indication that doses greater than 20 mg per day were more effective.</ao:suffix>
    <ao:exact>Benefit is less clear for women with ER poor breast cancer in whom the proportional reduction in recurrence was 10% (2p = 0.007) for all durations taken together, or 9% (2p = 0.02) if contralateral breast cancers are excluded. The corresponding reduction in mortality was 6% (NS).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4308DA5-4474-492B-AFCD-CFEE3F159D1C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-06-01 20:31:15 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:88108367-19A1-4D00-B6EB-78B390C12A84">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00458</dailymed:pharmgxDrug>
    <rdfs:label>Imipramine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:518D89E7-C4E7-42C6-A37E-48F86BA012B4">
    <ao:body rdf:resource="urn:linkedspls:uuid:7B77509C-B4A9-48D8-8281-20CE902E914A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-06-01 20:50:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:45F7DA71-DCBA-4667-AD78-F695417EFD56"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:043A8FED-C2FF-4047-BA84-C4896E5062DA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D9AAB24E-347C-44AC-9337-70D4C8D31CA1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E59B98C-D1FE-41D7-81D3-C3A9E7617BAD"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:8DD38833-252C-4D6E-9B42-D0FFA4AAF4D1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A7F3E5E-6959-4CA8-96DF-BDA1088E6D85"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:69C1542B-D7E7-491A-A589-9E0649208AE9"/>
    <pav:createdOn>2014-06-01 20:43:17 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:E52D7AF5-8AC1-400C-B035-9C0F0E0306F6</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B967963-2C76-436B-9F36-EE57DE7CD58D">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C4606DC4-9987-46D2-AA73-4BD4170A1631">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(43685-7) WARNINGS AND PRECAUTIONS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43685-7) WARNINGS AND PRECAUTIONS</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D296E2A7-2EC2-4235-B5FF-1E4E1D76F5D4">
    <pav:createdOn>2014-08-04 13:31:48 -0400</pav:createdOn>
    <ao:prefix> </ao:prefix>
    <domeo:uuid>D296E2A7-2EC2-4235-B5FF-1E4E1D76F5D4</domeo:uuid>
    <ao:suffix> In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D296E2A7-2EC2-4235-B5FF-1E4E1D76F5D4"/>
    <ao:exact>Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOMPIRAMINE-4074b555-7635-41a9-809d-fae3b3610059.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B901F682-13D1-4291-9125-3CD610827426">
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF0C66C0-7137-472E-BF75-5A95C688E1F2">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:169A7E8A-4D12-410C-81E5-561DCA16974F">
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA5BC6C6-51FF-46CE-ADC1-5C02EC5D7723">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:32C7D92F-8B7C-4FC1-BE72-43A4987726AC">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4DD032C9-55D0-4331-9441-E2547D5E5816">
    <ao:exact>In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined</ao:exact>
    <pav:createdOn>2014-06-11 13:42:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4DD032C9-55D0-4331-9441-E2547D5E5816"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>. </ao:prefix>
    <domeo:uuid>4DD032C9-55D0-4331-9441-E2547D5E5816</domeo:uuid>
    <ao:suffix>.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:836A37A7-4D0B-4AFA-8D09-94C3EA62FCE1">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(68498-5) PATIENT MEDICATION INFORMATION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(68498-5) PATIENT MEDICATION INFORMATION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3655BA22-5D0B-4E5E-A3EF-FE724755AAE1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:046418E6-0A19-45CD-9A54-BE4F20ABBB35</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:3174E059-41C2-4ACF-AA48-3133D48E6772"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:81252757-46D6-4D29-93CB-6BE7FED5A9A4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7C041AF4-2D3F-44DE-9C7C-2C3E27E3C77A"/>
    <pav:createdOn>2014-06-11 13:36:21 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:26F559B1-5DFA-4EBF-BEA5-4446B69F0CCE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:19FFFAA8-45DF-4BF9-9289-281EBDF38F90"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7792C95F-0D5A-4A19-913A-CFD050D291C3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F9BC4EC-8268-4066-9F9B-7A3A397C25CF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4065A9B1-96D6-4013-A8E4-92A374715A68"/>
    <pav:lastSavedOn>2014-06-11 13:36:21 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2B858186-07FF-44BE-863D-05D40DD39D4F">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9FBD8FD1-24C2-473F-A864-16F7B7D1D3F9">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9FBD8FD1-24C2-473F-A864-16F7B7D1D3F9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:suffix> (1.1)</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-06-01 18:44:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47F5DF8D-6E93-4BEA-B0A0-65FBF75E4A01">
    <ao:body rdf:resource="urn:linkedspls:uuid:AFD6F26E-7280-4ECC-9675-EB5879DA5B53"/>
    <pav:createdOn>2014-06-02 11:38:36 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD16BE80-5B8E-43B8-B9F5-17051DEF6533"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:715FBAF4-B02C-4176-9F1B-0A9DD25FB455"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F5428A8-04B1-4598-99C2-43DB74E0B647"/>
    <pav:previousVersion>urn:domeoserver:annotationset:9388AA14-511A-422D-96D9-2C12EAEAF089</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:994E0CF7-0D24-46F2-9307-D7615779EC81"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:546478F7-7C88-4C9A-B137-679B6C0B0C4A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:79A7B917-A122-4B38-B666-8BFEE9FD1385"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <pav:lastSavedOn>2014-06-02 11:38:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2ED739B4-0C5F-4523-B4E9-9392184D80A5"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF4B710F-A32F-47E2-BECB-106A837F1F66"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E84A315B-C921-4512-B11A-846BE09D8237"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16647501-DBAD-4E73-BB9F-26FCEC76D113">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AFD6F26E-7280-4ECC-9675-EB5879DA5B53">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C4A79FC-72E3-433A-9BE3-9ABDFE3AE46D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D99EFAC-2755-4CDE-8D9A-AAD020C8B927"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1E5BCF5-10F0-4E64-9946-E346FE9491EB"/>
    <pav:createdOn>2014-06-11 14:07:46 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5949CBDA-9167-433C-95A5-81DFCA48C5B6"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:8AC02895-0398-4206-B5B8-5D394A99F4A7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:500DFBF4-B18A-4741-B094-607CF87944D6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E525148-0789-4948-B85A-293C5034E5E3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A46F543-9241-436B-B829-9D81FA185E51"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-06-11 14:13:32 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:75D7A55D-3E2B-472B-884C-A63AD284F1F4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A474F9B-72D8-4812-A11D-7ECC770275F5">
    <pav:createdOn>2014-08-04 13:37:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>).</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/NORTRITYLINE-e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
    <ao:exact>Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA</ao:exact>
    <domeo:uuid>5A474F9B-72D8-4812-A11D-7ECC770275F5</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5A474F9B-72D8-4812-A11D-7ECC770275F5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2412BBA1-8042-4E16-BB46-9010B035CC06">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A3AAD6E7-A54A-4B2F-9829-90E41688953C">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:402EEAA2-F9CC-46AF-9550-E45E115692FE">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39C5C1E8-D80E-4CBB-99A0-4AB410862B09">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#absorption-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in absorption of the drug.</dct:description>
    <rdfs:label>Absorption Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:04539A04-F082-4C33-9B14-C8B5A2B0E0B5">
    <sio:SIO_000111>(34071-1) WARNINGS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34071-1) WARNINGS</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3FC2FDC3-15E8-4CB3-8CA4-01B7647070B0">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>I split this and the following annotation up to make the distinction between the different test results</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A3EAAFCB-A332-4199-ACDD-37AE73358A81">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1189C85F-D642-43D3-8F2D-A1796624A506">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7D1991F-37FC-467F-8870-C6D9F2ED65ED">
    <ao:body rdf:resource="urn:linkedspls:uuid:939C0307-55CE-4736-AA11-38175F4EE10A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:32DCFD4A-6714-434C-AA86-D67DC3A89BA4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:836A37A7-4D0B-4AFA-8D09-94C3EA62FCE1"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:77D0D8B2-83A4-43B1-82A7-ABE5233A32EE"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD1D3598-88CE-46BB-AE4F-E410622B3983"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-01 21:05:18 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:7CF9EE50-16A4-4EA2-B576-E055C8795A9D</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:lastSavedOn>2014-06-01 21:05:20 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:10DE53A3-0606-4583-BA2D-25D07EA38D58">
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC49AA35-6797-474A-BB56-1839ED9472BD">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB6A205D-3B24-4ACE-BA36-840F37E96BB0">
    <ao:body rdf:resource="urn:linkedspls:uuid:A6B0837C-86BF-4590-B20A-E91082C8094B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F4E8ECC9-9F2F-43A2-A7E0-A01C7E9DC8F1"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA7268BD-8AFF-4A8B-B305-FD1FD062230B</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-11 13:28:45 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C59A6BE-0F50-4E5A-80AD-A6BA98CD420D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3B40785C-7EC5-4FE5-AB93-76DB843730F0</pav:lineageUri>
    <pav:lastSavedOn>2014-06-11 13:29:53 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:44423DFB-386B-41D4-A5E8-35AB0C33FE19"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A49AA2B-31C9-4E3C-9873-E0CF6F23B89A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2322D8A4-E687-416C-A663-2B4F6EB929F7</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:768262D8-96AB-41E7-9186-5A319FC41A28"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7ED466C0-DE8A-4E8F-8C19-27DCBA31DFE8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4105FC79-40C4-4871-91B4-A09003C780CB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:77990241-ECCC-44E1-A79E-059C33CE6822"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9B637F2E-1396-48B0-A39F-67DC22C2A984">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8CB87CCD-6C94-40E2-8574-49EE07C75E57">
    <rdfs:label>Letrozole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F18267F5-8923-48E3-B45F-EAC7D10A80A8">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3798B8E0-BE90-4DE0-BCFB-27A121124827">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77A4C9B5-BEEE-43A9-B8F4-6B4BC1533760">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C014A5BD-94D4-4BDC-8DE1-11AC0D8384FD">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD5492F7-2EFF-4A23-AE94-6DFD182D578B">
    <ao:exact>About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients</ao:exact>
    <ao:suffix>.6,7</ao:suffix>
    <ao:prefix>.5 </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-11 13:49:48 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AD5492F7-2EFF-4A23-AE94-6DFD182D578B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>AD5492F7-2EFF-4A23-AE94-6DFD182D578B</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25A004DF-00A0-434B-857D-AD64FE5F5005">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C1B6E5EA-2C52-46E8-A53F-9B074F8E312B">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:546478F7-7C88-4C9A-B137-679B6C0B0C4A">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4105FC79-40C4-4871-91B4-A09003C780CB">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0ACBA9FB-1386-45B7-A361-3F22E768F627">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D33A037-01E3-4544-9149-0E57600DD51C">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen in these patients.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1D33A037-01E3-4544-9149-0E57600DD51C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-01 20:50:40 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>re not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Healthcare Professionals can obtain a Gail Model Risk Assessment Tool by dialing Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX). </ao:prefix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD865684-8CE5-4ED5-AA78-F871917481B3">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB3D4737-FF1A-4D5E-B37A-516341298372">
    <poc:Comment>assumed 2D6, </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C3AC9B3-D601-4136-A811-7C38BDF19C43">
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25DA647B-FA49-4F68-92F1-7B4508C1AD2A">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00252</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Phenytoin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EAA417CF-C05A-4863-A358-42D28D8EC5FC">
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB813A63-3B67-4CF1-851E-23758D0439A8">
    <domeo:uuid>CB813A63-3B67-4CF1-851E-23758D0439A8</domeo:uuid>
    <pav:createdOn>2014-06-11 14:00:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>DOSAGE AND ADMINISTRATION : Laboratory control ). </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CB813A63-3B67-4CF1-851E-23758D0439A8"/>
    <ao:exact>Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A645FD45-0632-43FA-998C-381B1EA9E76D">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49957CE8-4BDB-49B5-899D-F9140D2F0B6B">
    <pav:createdOn>2014-08-04 13:37:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> </ao:prefix>
    <ao:suffix> Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:49957CE8-4BDB-49B5-899D-F9140D2F0B6B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>49957CE8-4BDB-49B5-899D-F9140D2F0B6B</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/NORTRITYLINE-e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called âpoor metabolizersâ); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1488A565-393F-4193-95C9-2E2B6E284AFD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FAC3AAC8-B0C8-4681-A502-DAD45238EB0D">
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:241AC904-E593-4A48-9E32-7846142BF6D0">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62C44EE7-9565-49BB-8348-F00484C13CA9">
    <pav:createdOn>2014-06-02 11:40:20 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:62C44EE7-9565-49BB-8348-F00484C13CA9"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:prefix>Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>62C44EE7-9565-49BB-8348-F00484C13CA9</domeo:uuid>
    <ao:exact>The estrogen- and progesterone-receptor values may help to predict whether adjuvant tamoxifen citrate tablet therapy is likely to be beneficial.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:166E1275-A150-4DA6-9690-B18CDA86FA54">
    <ao:body rdf:resource="urn:linkedspls:uuid:BCFB7B91-25DB-40CF-A05D-7A83778BB16D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ADBCACC3-7EC0-4C1D-9D18-9AC317502BF8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:364E48E3-9581-476A-B552-7EF20E3B5123"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE4EC397-CC34-40DB-8366-77AACB51DEAB"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:370AB788-B410-4EF4-A015-06EEAC3F3446</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:49ACD5A8-48E7-4C4E-A4B9-DAF372EB24DC"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:07689067-83B2-4A59-B4F7-83DFCFA0ED5D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B967963-2C76-436B-9F36-EE57DE7CD58D"/>
    <pav:createdOn>2014-06-01 20:17:53 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:63CB3359-94D1-40EE-AF4F-853814B8E2BE"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <pav:lastSavedOn>2014-06-01 20:20:47 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:182124B1-5996-466F-858E-FC532C12BD72">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C647CEF6-6BF9-4822-89CB-25C5E2F54D09">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A34B301-47EA-4BF6-B389-C650617368B8">
    <rdfs:label>Voriconazole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00582</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:88C15D26-B0E7-4BA6-B4B5-711DC61447C0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94089BCA-C215-4C7B-A9A4-7683F963DE3D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE4EC397-CC34-40DB-8366-77AACB51DEAB">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4BA538D-61A7-4EAD-8570-A3A806489044">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>3A4 should be added to HGNC Gene Symbol Selection
Rifampin
letrozole 
tamoxifen </poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4A4214A-FDFF-4CBD-87E9-A1016E1FC8C8">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A4A4214A-FDFF-4CBD-87E9-A1016E1FC8C8"/>
    <pav:createdOn>2014-06-01 18:43:11 -0400</pav:createdOn>
    <ao:exact>Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55CB7EF8-A6B6-4D3F-9A7F-DCF6A7E08FE4">
    <poc:Comment>Highlights section</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9EE5574C-5B47-4322-8BF3-62AB4B50ED0B">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D2D084F-6A5B-4E87-9B36-958F2E5BA705">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:606B5431-4B53-4BD3-9EAE-394BFF580265">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00252</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Phenytoin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4E8ECC9-9F2F-43A2-A7E0-A01C7E9DC8F1">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:48BF451F-8ED4-4DCE-BA4E-2A7F92633EAE">
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AF079F40-0025-456F-8288-81DF3604F1DA">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DACE1DF5-0195-433D-951A-A7CBDCE6CEAA">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA9BC8D1-0537-43CA-9563-9EE677C227D5">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F44327B4-A42F-460E-9D93-C700B8391D1D">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3ED74D87-17C8-4371-908E-0ED43A8E305C">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>3A4</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:983564B3-9258-48BE-8693-C04C2636E88E">
    <domeo:uuid>983564B3-9258-48BE-8693-C04C2636E88E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:983564B3-9258-48BE-8693-C04C2636E88E"/>
    <pav:createdOn>2014-08-02 10:43:12 -0400</pav:createdOn>
    <ao:exact>Rarely, unexpected, severe toxicity (eg, stomatitis, diarrhea, neutropenia and neurotoxicity) associated with 5-fluorouracil has been attributed to a deficiency of dihydropyrimidine dehydrogenase (DPD) activity. A link between decreased levels of DPD and increased, potentially fatal toxic effects of 5-fluorouracil therefore cannot be excluded</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7044D8AD-2E9A-4764-8005-C08DC9ACB3C5">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not change the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-change-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Not change from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6646F47-309F-4535-A926-D22F26209907">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5999E193-A258-4C6E-8E0E-1460FC80FFD4">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Drug selection question </poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:817D0D50-B6C9-432D-AC7F-9F2A5208CBDA">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nde51ee3ee1974e839ee60f86a861636f">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:965254E7-B87D-4A3D-A34F-21420503EE36">
    <domeo:uuid>965254E7-B87D-4A3D-A34F-21420503EE36</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <pav:createdOn>2014-06-01 17:59:20 -0400</pav:createdOn>
    <ao:exact>Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:965254E7-B87D-4A3D-A34F-21420503EE36"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8369C922-5F94-4382-A0B9-A7423698A59D">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>8369C922-5F94-4382-A0B9-A7423698A59D</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8369C922-5F94-4382-A0B9-A7423698A59D"/>
    <ao:prefix>re not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Healthcare Professionals can obtain a Gail Model Risk Assessment Tool by dialing Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-02 11:44:28 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:exact>There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen in these patients.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DB2EAE02-3287-49AA-9FDB-D44A830B56BF">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D99EFAC-2755-4CDE-8D9A-AAD020C8B927">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:944E2306-B45C-43F2-9DD4-DBE4D03BAEFC">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:24EFE4BC-3895-4D41-9ACB-83753AC5B633">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:32DCFD4A-6714-434C-AA86-D67DC3A89BA4">
    <poc:Comment>BRCA? \nESR1 used as a place holder\npatient medication information?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EFF7AFC3-9668-48B3-8D90-C3D7A5C411AE">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1BDAC9B-609B-4C7E-B58C-1EBA49888DA8">
    <ao:body rdf:resource="urn:linkedspls:uuid:B1138F44-9FEE-4242-8404-881C86C069D3"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:8AB3F2D0-8322-4A48-B07A-0D5ECB04CB02"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8000C8F-8664-487A-B6F5-84E4C4319FE2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D811D5CC-451D-4E8E-9447-9B6228329CAC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-01 18:15:49 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE4B0A7F-465B-4C17-852A-BF262924757C"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:D6A95D34-55A1-472A-A095-901E6BA00830</pav:lineageUri>
    <pav:lastSavedOn>2014-06-01 18:15:49 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:38B40CF7-C8FF-4523-8FCC-9DD4D66AD8E0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:E9375FA9-EB77-4EFD-A836-7C6191A16725"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:266752F2-12DA-4D05-A515-48ED6004FC91"/>
    <pav:previousVersion>urn:domeoserver:annotationset:3DA5215F-6629-42E2-871D-11E3D7F8A9A5</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:ED1438B9-484C-417F-81FC-9615F534707B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB3D4737-FF1A-4D5E-B37A-516341298372"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:10F685C2-516D-430A-8891-5F34A306C727"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4692FB98-A64C-40B7-B39D-39E13B9E1BD1">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DCCE915-58E2-43D0-8882-0D587754658C">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD16BE80-5B8E-43B8-B9F5-17051DEF6533">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Clinical trial indicated = available evidence?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E09C5817-9861-40D2-88DF-8866F982C841">
    <poc:Comment>double annotate </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35FB2E8E-AD51-4F49-993D-2C68F0FDE171">
    <pav:previousVersion>urn:domeoserver:annotationset:1643D737-5188-4795-9C3E-1361D4D71262</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:1461839B-2331-4FA6-B624-FD2100276C0D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:33049BC0-4665-43EC-8226-84723CC7AC54"/>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D075A98A-6E8D-4058-8053-C50ED33E10AC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:669C65A2-428A-40D8-AB6B-42D149C8F608"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E22833FF-9C8C-4AAF-BF61-7A1BAC88B9EE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E80AFBE-0A52-4745-AE9E-9AB372773FFD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CC422AD-3150-4062-B2B7-734941FBC7FA"/>
    <pav:lastSavedOn>2014-06-01 20:28:40 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-01 20:27:46 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:339670C1-0475-4E89-9865-932C014CDE44"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E0D86EDB-C3C6-4949-ADD3-3C324B912356">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006678</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>DPD</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8840FB3B-47B3-4958-864C-619B7A4F6927">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AED49CB9-4E63-4554-BD0A-FA513B375D56">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B30E27C7-9FC2-49F9-8322-0F737014ACC2">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C49E36DE-5ECE-4AE4-8054-4C31FF132938">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1, PGR</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44301F97-7088-46C4-BB32-27D413FE3A60">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>G20210A?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:41D66BF8-B50B-49AE-9485-093AD9465BA2">
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <dct:description>Referred to Prodrug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79A7B917-A122-4B38-B666-8BFEE9FD1385">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AF3691C6-184F-4B0B-A35B-2A7D10DECD85">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#distribution-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Distribution Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in distribution of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FD368524-6F09-4376-AC8C-D75A9A387A2B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49E4005A-EE50-404F-A52D-3249F8464394">
    <pav:createdOn>2014-06-02 11:44:28 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:62F162C4-135E-4C80-90D5-5AE8570228F2"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:43BE40DF-E3A1-4B18-861F-5F151D1E6E92</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:BED2D48F-56C7-41B5-8920-32197D90ECAF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E1913406-D5F7-4C32-A307-A55268FB07FA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A9B2E784-E7B7-4BE7-9644-C8BAC52301DD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-06-02 11:47:08 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA5CB1FD-D1F7-4527-A5EC-8F6AD26EDF25"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:270E4F6D-B8A5-47C4-AC1E-6B8F995D7933"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8369C922-5F94-4382-A0B9-A7423698A59D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6207BDE-B892-441F-BE0A-0D7E3B0CC6B7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA8988F3-1346-4B78-A914-D18381CEF56A"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BE7C7835-7F73-4770-8C90-0BB58BE1F330">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0672652F-D2D6-4850-B292-41777DDD93A4">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB38CF6C-6593-4ED5-BBC9-F6406EDC1134">
    <pav:createdOn>2014-06-11 13:43:01 -0400</pav:createdOn>
    <ao:prefix>.</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EB38CF6C-6593-4ED5-BBC9-F6406EDC1134"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>EB38CF6C-6593-4ED5-BBC9-F6406EDC1134</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:739A5BD0-8B81-4858-8716-A365FFDAC30C">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*1502</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A25A28C-E3A8-4E68-AE36-EFD658F4D76F">
    <ao:body rdf:resource="urn:linkedspls:uuid:EC560B3F-80E8-45DF-8C22-E3764D8A78E3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:29724897-7FCC-4FE3-8892-8BA2C20F9F46"/>
    <pav:lastSavedOn>2014-06-01 20:28:23 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:2412BBA1-8042-4E16-BB46-9010B035CC06"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F22F3EF-3DEC-46A7-8991-5011D63F1093"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:928318F4-75B6-4942-841F-EEAC3724CEC6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7852C3C0-B9AF-40A3-9E8D-CCC1804296A0</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:24950A77-AA81-4C28-864F-AEDA923C8518"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E0A9BA42-4FB0-46B6-BAF5-795971CA1806"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:8CB87CCD-6C94-40E2-8574-49EE07C75E57"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A2643A08-C95E-48C6-930F-8CE9B9775384"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdOn>2014-06-01 20:25:43 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:836CABF8-8E8E-4739-8AF2-34CCA31278ED"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:24950A77-AA81-4C28-864F-AEDA923C8518">
    <sio:SIO_000111>(34090-1) CLINICAL PHARMACOLOGY</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34090-1) CLINICAL PHARMACOLOGY</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:49158C09-A374-4459-AC9A-A986E180C807">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:777356F6-9617-4A7E-BF6D-EC58735B2B5D">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>unknown and positive = separate annotation
maybe no need for second sentence?
</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:76AD476F-C289-424C-B080-FF9FDC1BB77A">
    <poc:Comment>double annotation</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6894BC08-84DE-4272-B1B2-1CCDD5AF8ADD">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B51718B4-5A16-4E25-86C6-63E480554AE3">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2EC9FFBC-39E6-4792-A7DA-C8D1C024066E">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E8A6E52-FD5A-424D-B3DC-0D2BEE977A6B">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:563D84AA-9BEE-4BA8-8D08-3A4F5F473A1F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>pk pd impact implication or specific?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A270632-99AC-42BD-BA80-93F264DC803C">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34078-6) NURSING MOTHERS</poc:productLabelSection>
    <sio:SIO_000111>(34078-6) NURSING MOTHERS</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:76EA7D30-E3C4-4197-A7B4-293995F38E7C">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#addition-of-medication</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Addition of medication</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to add a concomitant medication.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B46F04DC-85C8-4982-8ADB-7231FDAE4913">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC26B2F3-DCB0-45D7-AD56-ADA3439144E5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:72BD3694-98FC-40F3-B2A3-1555044DD90D">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B188F4B3-BEE4-4198-BC13-07F018492D84">
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:824A4432-39BC-49ED-8538-4C4DF2FFF7E9">
    <pav:createdOn>2014-08-02 10:45:00 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:hasSource>
    <ao:exact>DO NOT TAKE XELODA IF YOU\nâ\nare nursing a baby. Tell your doctor if you are nursing. XELODA may pass to the baby in your milk and harm the baby.\nâ\nare allergic to 5-fluorouracil\nâ\nare allergic to capecitabine or to any of the ingredients in XELODA\nâ\nhave been told that you lack the enzyme DPD (dihydropyrimidine dehydrogenase</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Who should not take XELODA? 1. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:824A4432-39BC-49ED-8538-4C4DF2FFF7E9"/>
    <domeo:uuid>824A4432-39BC-49ED-8538-4C4DF2FFF7E9</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E0A9BA42-4FB0-46B6-BAF5-795971CA1806">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D075E9C9-B7BD-48C6-8355-DD2C9A3FCA33">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:12247663-6D8E-4333-8FCA-0EC431436874">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF45D32B-2C77-47D2-A0CC-3F4EB3D7B129">
    <pav:createdOn>2014-08-02 11:29:32 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AF45D32B-2C77-47D2-A0CC-3F4EB3D7B129"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In vivo studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 15â20% of Asian populations may be expected to be poor metabolizers.  For Caucasians and Blacks, the prevalence of poor metabolizers is 3â5%.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/VORICONAZOLE-ce3ef5cf-3087-4d92-9d94-9eb8287228db.html</ao:hasSource>
    <ao:suffix> Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolizers have, on average, 4-fold higher voriconazole exposure (AU</ao:suffix>
    <domeo:uuid>AF45D32B-2C77-47D2-A0CC-3F4EB3D7B129</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5C205E24-92C4-484F-9EAE-03E0827A96AF">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7BFBC3AC-D8B5-415E-AB79-C58932414E1C">
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:603D28B5-7467-45FC-88C4-58C305EE9549"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:14A4B8C7-A2F8-4432-9D84-03A047BA880A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AED49CB9-4E63-4554-BD0A-FA513B375D56"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:777356F6-9617-4A7E-BF6D-EC58735B2B5D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB28026C-C47A-45ED-AA26-E514F6865F6C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4999A1DA-C288-46D8-A62C-B991C9A4B2F7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FD29F999-6BE6-4296-85E2-66DAA123889B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:370AB788-B410-4EF4-A015-06EEAC3F3446</pav:previousVersion>
    <pav:createdOn>2014-06-01 20:20:14 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-06-01 20:20:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF508BF5-0707-4BB5-9669-06BE9AD4A04C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:43639865-D15D-44CD-B29C-C1DE608FAC81">
    <poc:Comment>does the ER positive/ ER poor influence the test result?\nI struggled to use this statement.  It seems important to include because it directly correlates with the biomarker levels in the patients being used in the study, but should it stand alone from the rest of the study?\n</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E33A87B-4D10-4EEB-9474-B2DE755BB787">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47AA611C-52F9-451D-A32D-B74772D95E1D">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Not all patients with these conditions develop necrosis, and tissue necrosis occurs in patients without these deficiencies</ao:exact>
    <domeo:uuid>47AA611C-52F9-451D-A32D-B74772D95E1D</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:47AA611C-52F9-451D-A32D-B74772D95E1D"/>
    <pav:createdOn>2014-06-11 13:57:32 -0400</pav:createdOn>
    <ao:suffix>. Inherited resistance to activated protein C has been described in many patients with venous thromboembolic disorders but has not yet been evaluated as a risk factor for tissue necrosis. The risk associated with these conditions, both for recurrent thro</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F402EF1E-1334-42ED-A999-EE7766099656">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11FA8543-EFAE-41BB-AC14-B3FBE08DCAC3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D2AE312-F185-429F-9003-FDA4E74523C6">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:836CABF8-8E8E-4739-8AF2-34CCA31278ED">
    <ao:exact>The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-01 20:28:22 -0400</pav:createdOn>
    <domeo:uuid>836CABF8-8E8E-4739-8AF2-34CCA31278ED</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:836CABF8-8E8E-4739-8AF2-34CCA31278ED"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:suffix>In postmenopausal women, estro</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A2DE966A-0E58-4329-AC3F-EB75F66C6321">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34070-3 CONTRAINDICATIONS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34070-3 CONTRAINDICATIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44B83470-7A63-4402-A977-48C1847BDF4D">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45BA0CBA-7217-4D45-8C6B-F3247F353A9F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Letrozole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:85062DD4-AC27-4671-801E-7592AC985BD2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:427</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ALK</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A3D5CE0-5494-41FF-93AA-12BE6B105CB5">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD943268-375C-4FD3-BF66-1B7A4E7165D3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34068-7) DOSAGE AND ADMINISTRATION</poc:productLabelSection>
    <sio:SIO_000111>(34068-7) DOSAGE AND ADMINISTRATION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5EF2DA97-251F-4040-B369-991E5B94F590">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <rdfs:label>VKORC1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:09CFCA72-AD6C-45E3-A210-C2FDA3847192">
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FDA62776-5111-4CFD-B790-89C343774C0D">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>CYP2D6*1/*1, CYP2D6*1/*2</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B8FA7095-4EDB-4DF4-9EAC-A4BEACE8D15F">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A0A7D04-0499-4BEC-88CB-133571A2B9AF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>XELODA is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.</ao:exact>
    <pav:createdOn>2014-08-02 10:34:19 -0400</pav:createdOn>
    <domeo:uuid>9A0A7D04-0499-4BEC-88CB-133571A2B9AF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9A0A7D04-0499-4BEC-88CB-133571A2B9AF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CFA9A1B1-F6CA-4A27-A169-261051BF3E8A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E7424CE2-FD6C-4DBC-BFB5-42DA271DD71D">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4065A9B1-96D6-4013-A8E4-92A374715A68">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D36764F-323E-47A6-B290-5C391ADD84BA">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1461839B-2331-4FA6-B624-FD2100276C0D">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1461839B-2331-4FA6-B624-FD2100276C0D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>1461839B-2331-4FA6-B624-FD2100276C0D</domeo:uuid>
    <pav:createdOn>2014-06-01 20:28:39 -0400</pav:createdOn>
    <ao:exact>The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women.</ao:exact>
    <ao:suffix>In postmenopausal women, estro</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA82B2B8-D75E-48D2-805D-7373ECD081EA">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F756ED20-FA04-4BDF-BC09-9FBC85BDC887">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34A8CD45-16CD-4C75-9AA8-BB2B781A2681">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D4C0D8A-FED7-4829-92D0-676FF52D8604">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Attempted to duplicate this annotation in the black box under Full Prescribing Information -- Repeatedly placed the additional annotation over the text in the first black box found in the highlights section. </poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE07F18F-F19C-4F49-975C-232A47227ABA">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C11BE719-29B5-4CB0-8D19-154841DA98A7">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2041E76D-52F2-403B-AC36-D990EF008C61">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:32E1E9EA-32B8-460F-B557-2CA8E3B4CC01">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B34B407B-DA7B-48C1-A77E-AC097227B8B5">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A354BAB4-08FF-4889-889F-705F226C1E47">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>CYP2C9*1, CYP2C9*2</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3219E3B4-644F-4DCE-8741-7846947834CD">
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CE087B1D-B7B6-43D4-80F5-1F284A6E2CFB">
    <rdfs:label>VKORC1</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:64D3B7C7-C42E-4D2D-A22A-EC0C09CD1FAA">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>respiratory depression, death, extreme sleepiness, confusion, shallow breathing</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0d6be00b8db54fa5a9348515f28d3f3d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6BBC9479-F11A-4B2C-A0B5-80B1F2C47315">
    <poc:Comment>metabolism? metabolism vs clearance?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:097E8AC0-79CD-44CA-BE54-2CC0BBF0008F">
    <ao:exact>About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>097E8AC0-79CD-44CA-BE54-2CC0BBF0008F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-06-11 13:50:34 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:097E8AC0-79CD-44CA-BE54-2CC0BBF0008F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>6,</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1491F2F7-B153-44DD-9D3B-6111C922E0AD">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CDA25E4F-5AD6-49AC-BFDC-FB737EF18E43">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FE997C42-A3EA-417B-AB18-79D16C65178F">
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7C8DABC-CB6B-4C4F-8514-4FA6E4C2B5D1">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00540</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Nortriptyline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:731E542F-F12E-49C7-891D-55159666E4E6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D93C557-7BA6-4DCF-B075-71C884D5D59F">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9B9279C7-658C-406C-946D-9BFF5C459B06">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA1A5436-6353-49E0-B158-D24D32105570">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>BCR/ABL1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:76</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A82CF14A-DCB1-4B86-8F03-654B6F950040">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00D3633A-8196-4872-83DB-5800718FB971">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ADBCACC3-7EC0-4C1D-9D18-9AC317502BF8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:781BBA63-F58B-4E56-AD8A-0062F37377E4">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:063BE245-52EF-45FC-8786-26709F5717B6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:548EFA8F-26D0-4768-A40E-4B8E244415B1">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:548EFA8F-26D0-4768-A40E-4B8E244415B1"/>
    <ao:exact>Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient's VKORC1 genotype</ao:exact>
    <pav:createdOn>2014-06-11 12:45:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid>548EFA8F-26D0-4768-A40E-4B8E244415B1</domeo:uuid>
    <ao:suffix>. Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:95C516F2-F188-48A9-AA27-93B80D64DEBF">
    <sio:SIO_000111>(34081-0) PEDIATRIC USE</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34081-0) PEDIATRIC USE</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD1D3598-88CE-46BB-AE4F-E410622B3983">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B9704426-CE3F-49D8-B1BA-14F8EDD6988F">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91136920-A36A-4336-B15B-F7BD77B74823">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8767FAB4-E332-486A-BF44-4F093B1A29F5">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7841625B-9726-42EA-AA7C-920793ED16BB">
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7ED466C0-DE8A-4E8F-8C19-27DCBA31DFE8">
    <ncit:Alleles>CYP2C9*5, CYP2C9*6, CYP2C9*11, CYP2C9*5, CYP2C9*9, CYP2C9*11</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D3B9099-D4D4-4D0D-BB45-DACEAE2FC2E3">
    <domeo:uuid>0D3B9099-D4D4-4D0D-BB45-DACEAE2FC2E3</domeo:uuid>
    <pav:createdOn>2014-06-02 11:47:03 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In a small substudy (N = 81) of the NSABP P-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0D3B9099-D4D4-4D0D-BB45-DACEAE2FC2E3"/>
    <ao:prefix>nistered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects. For treatment of breast cancer, the risks and benefits of tamoxifen should be carefully considered in women with a history of thromboembolic events.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:165E829E-984A-494F-8AB3-893041E5DEFC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33049BC0-4665-43EC-8226-84723CC7AC54">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdfs:label>Letrozole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0BCB85F-4E9F-490F-A26B-7F167BCFBF49">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3FCC9F3C-187A-4D10-B907-FACC9E668E85">
    <poc:Comment>inhibition of CYP P450?
enzyme genetic? 
I am confused as to why this is not highlighted by anyone else
</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:363BDC0B-DE13-492B-A8A9-813EB5CD33BF">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6556E663-F80F-43E2-A71E-4CAD11EF29B0">
    <poc:Comment>SJS/TEN, Asian ancestry, Chinese Ancestry </poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C4FF148F-DA8E-460A-9416-12EABD3C0787">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer, postmenopausal,</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F9F0CCA-B6E8-41D6-84C8-186912D7E20B">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000004801</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>BRAF</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E9A7644-D20B-4E3E-BC6F-7B20E01712E0">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00540</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Nortriptyline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8C6C1DB3-50EA-4E8C-9744-0620557B06F4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96A0F5F4-831E-46D5-8A29-337ED9DE5940">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FFDA2233-33BA-4536-AF73-6526806736C1">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01101</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Capecitabine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1FE38B13-8404-4584-A556-793401619B3D">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11BB99CC-6A33-487D-B318-019C7709AEEF">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3012</dailymed:HGNCGeneSymbol>
    <rdfs:label>DPYD</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C2CCDBA6-0295-4B86-8110-E1D72B2564B5">
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA9E42CC-F1E7-4CFD-AED6-F74E23CA07BD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E8D60E72-87CF-4F20-8B7F-3DE216B184DD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:1483C104-1035-4F90-B6A1-E546F30356A4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:43639865-D15D-44CD-B29C-C1DE608FAC81"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E93E67E-7C76-44BE-AFE1-D5AE75C92344"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:lastSavedOn>2014-06-01 20:26:56 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:C142C80C-93FC-4F4D-BB05-9AAD8A4ADFD3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C94E7B6D-85F6-4A00-8BE8-CCEEA58A9D9C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:961ABB97-90DE-483F-87EA-8A701EE196B4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:063BE245-52EF-45FC-8786-26709F5717B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C35CE08B-2D0A-445E-8FF3-98CB7A953446"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <pav:createdOn>2014-06-01 20:26:55 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FD3371AC-2CA4-4591-9FDB-F3F12C3F791F">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>double annotation</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C478D95-94FE-474B-B9ED-AA77113212FD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
    <rdfs:label>Not Important</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:834AA255-FB15-454F-98B9-72E0C8AA687F">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77990241-ECCC-44E1-A79E-059C33CE6822">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D9AAB24E-347C-44AC-9337-70D4C8D31CA1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:82A863E2-4600-4792-BDAB-897D7BCBB8A7">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Not change necessary</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#no-change-necessary</poc:DrugSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8DD38833-252C-4D6E-9B42-D0FFA4AAF4D1">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3174E059-41C2-4ACF-AA48-3133D48E6772">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:29724897-7FCC-4FE3-8892-8BA2C20F9F46">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>pd impact implication or clear cut?
no specific test recomendation however indicates there is one
estrogen and progesterone are in many products (does this warrent cocomitatnt med concern?

biomarker positive and unknown + 2 annotations?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B0EBE3D-E880-49F6-AED2-BCC056A7B6BA">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34076-0) INFORMATION FOR PATIENTS</poc:productLabelSection>
    <sio:SIO_000111>(34076-0) INFORMATION FOR PATIENTS</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:08D4AA9E-8ECC-4FCE-93FB-793BBFA64704">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2BCE2A5B-B080-4BF0-8C54-6DEC6EEE09D8">
    <rdfs:label>Phenytoin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00252</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0FFD0391-8E1C-417F-B431-7442EDC03CC4">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F6CA925-F781-4E8B-82F4-1C65CA1F0915">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43679-0) MECHANISM OF ACTION</poc:productLabelSection>
    <sio:SIO_000111>(43679-0) MECHANISM OF ACTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8757F043-1DF7-4DEA-8960-92BC05400D47">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3BA23D20-616C-4FB1-A929-A65950D7A2C3">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5086E51F-BE9D-4B26-994F-F65D1039BDE2">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B6734B02-ECA2-4C72-BF40-9F8C068486B0">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:89485073-562F-4DAB-B1DF-419C02ACA2B8">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:18576D93-9B30-4D84-A45D-3448E7139E8E">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:523071B4-7A9B-4843-94CE-574131C7DAB0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6FA1B68E-82C9-4FFF-943B-08856C6834BF">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DBC567B-06FC-4E32-AF97-1F12BA46DF14">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:765F61E9-DD3D-4283-9374-462AD82510CA">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01101</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Capecitabine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07BDCF78-FF4E-4E7B-B35D-B720E7D377B6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A5BFB7BD-0889-46E3-8363-DF3748E897E4">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>CYP2C9*2, CYP2C9*3</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:224663F4-07A0-4FBC-A16E-E7CC8E2BE4B3">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01101</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Capecitabine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBF04D85-16FE-4392-BAA3-393C676C0B40">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3F2F6001-FAD9-4998-BE98-36775E86BB95">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C94E7B6D-85F6-4A00-8BE8-CCEEA58A9D9C">
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:270E4F6D-B8A5-47C4-AC1E-6B8F995D7933">
    <rdfs:label>BCR/ABL1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:76</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:961ABB97-90DE-483F-87EA-8A701EE196B4">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77FA206B-E97B-4DB2-95C8-2CAEE18D73ED">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A02EB88-FB01-4216-A878-9EE08371A1E2">
    <pav:createdOn>2014-06-02 11:54:42 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2A02EB88-FB01-4216-A878-9EE08371A1E2"/>
    <domeo:uuid>2A02EB88-FB01-4216-A878-9EE08371A1E2</domeo:uuid>
    <ao:prefix>citrate tablets to reduce the chance of getting breast cancer? We don't know â¢ </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>if tamoxifen citrate tablets lowers the chance of getting breast cancer in women who have abnormal breast cancer genes (BRCA1 and BRCA2)</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4AD4C0A2-0B16-4B3E-A064-02C1FAD359BE">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>double annotation</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D2A4F1C-7ECF-457E-9105-89D4FAC2EAC4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF247ADE-CEC1-4294-951B-E346EEFCF880">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>???</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:057E63DB-B25B-4E76-9FB2-B358F7686200">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AF8DB776-902D-4D64-B696-3FC851874FB8">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>two separate annotations. this is one sentence the entire thing must be highlighted, but refers to both VOKRC1 and CYP2C9.</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2672E598-EC59-4170-9CB6-E1E32412FAF5">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
    <rdfs:label>gene-SNP-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8EA68AC5-1674-484B-B8D0-2AECA70B9FE8">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Naf54ad921c37440cacac3928dd3ff2e1">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52659CB2-2836-4827-AA04-68D75C4A4B31">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:923A77D4-C08D-44B0-862C-B0A9234FBFB9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F6360F7-C764-4F07-977F-14703344B18A">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2FE5A7C6-CC4D-4D04-882A-AF096D8A4799">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>double annotation</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3563965-B210-42C0-9FF0-A3486F2240E1">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdfs:label>Concomitant medication concern</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5060AA2F-563F-4BDB-839A-F3162FF7EA14">
    <ao:exact>There may be wide interpatient variability in phenytoin serum levels with equivalent dosages. Patients with unusually low levels may be noncompliant or hypermetabolizers of phenytoin. Unusually high levels result from liver disease, variant CYP2C9 and CYP2C19 alleles, or drug interactions which result in metabolic interference. The patient with large variations in phenytoin plasma levels, despite standard doses, presents a difficult clinical problem. Serum level determinations in such patients may be particularly helpful.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5060AA2F-563F-4BDB-839A-F3162FF7EA14"/>
    <ao:suffix> As phenytoin is highly protein bound, free phenytoin le</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PHENYTOIN-8848de76-8d74-4620-bcc7-a86a596e5dd9.html</ao:hasSource>
    <ao:prefix>In most patients maintained at a steady dosage, stable phenytoin serum levels are achieved. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>5060AA2F-563F-4BDB-839A-F3162FF7EA14</domeo:uuid>
    <pav:createdOn>2014-08-02 10:54:33 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9631DAFD-657D-4B15-B45C-6749370AB9DC">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A7F3E5E-6959-4CA8-96DF-BDA1088E6D85">
    <rdfs:label>Increased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6420B306-74DB-455D-BE43-AFBC96ACA818">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7065589B-D53D-4313-BEC7-33FABA8CE2E6">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1056089-0FB5-44D2-A976-B96EE2910380">
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BED2D48F-56C7-41B5-8920-32197D90ECAF">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-negative</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-negative</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CC422AD-3150-4062-B2B7-734941FBC7FA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>pd impact implication or clear cut?
no specific test recomendation however indicates there is one
estrogen and progesterone are in many products (does this warrent cocomitatnt med concern?

biomarker positive and unknown + 2 annotations?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C142C80C-93FC-4F4D-BB05-9AAD8A4ADFD3">
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:945AB3F9-D117-4A09-A4D4-85964D29ACAC">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:146074E6-D887-4B6B-A91C-D2BF04FB29EE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99A8346F-0797-4D61-8489-57A101437F89">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EDE6ABED-333B-4E42-81E0-6413B330BE7B">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00582</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Voriconazole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A51DC49-F45F-4CA3-A6F9-06104CA8B14C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Not necessary</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-necessary</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is not necessary.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69C1542B-D7E7-491A-A589-9E0649208AE9">
    <ao:suffix> In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:69C1542B-D7E7-491A-A589-9E0649208AE9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-06-01 20:43:17 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact> In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF508BF5-0707-4BB5-9669-06BE9AD4A04C">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:297B4881-837D-4A9C-A301-0F3EBE07A00A">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>double annotation</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F46F596-3A3E-4B21-BBEA-8C8155F1DEC0">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E495D799-FBD4-414C-B469-19EB5A801B2C">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3DA0ACFB-DBE3-4670-9096-B2693120E22D">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6B0837C-86BF-4590-B20A-E91082C8094B">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E1913406-D5F7-4C32-A307-A55268FB07FA">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>double check HGNC and biomarker (need to add)</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7762E8FF-2F66-49F9-8F33-6361BE15F2B6">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FD140441-800B-4DD9-BDDD-A11517ACBE7F">
    <ao:prefix>inistered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects. For treatment of breast cancer, the risks and benefits of tamoxifen should be carefully considered in women with a history of thromboembolic events. </ao:prefix>
    <pav:createdOn>2014-06-01 20:55:48 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In a small substudy (N = 81) of the NSABP P-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FD140441-800B-4DD9-BDDD-A11517ACBE7F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AD380829-33F2-467D-8FFB-C5E8CBD01FF5">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:82B4B70A-A7ED-4A04-9BB4-206EF37C2508">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>ESR1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C35CE08B-2D0A-445E-8FF3-98CB7A953446">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer, </poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D4B6D211-BD6A-4A30-AC82-12687AEDE502">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A59BB6E-2551-4B9E-975A-64B9A8EA2B15">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(68498-5) PATIENT MEDICATION INFORMATION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(68498-5) PATIENT MEDICATION INFORMATION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AA8627E-CA88-4386-8040-4A006B86F19F">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5949CBDA-9167-433C-95A5-81DFCA48C5B6">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:468FE543-AD1E-48C2-AEC2-929DA27DC15F">
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A2643A08-C95E-48C6-930F-8CE9B9775384">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>ovariectomy
adrenalectomy
hypophysectomy
breast cancer
cancer
progesterone therapy?
estrogen therapy?
tumor growth
tumor progression</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E80AFBE-0A52-4745-AE9E-9AB372773FFD">
    <sio:SIO_000111>(34090-1) CLINICAL PHARMACOLOGY</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34090-1) CLINICAL PHARMACOLOGY</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2623AB8-D307-4E32-8797-292B9D4C2A82">
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:339670C1-0475-4E89-9865-932C014CDE44">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>ovariectomy
adrenalectomy
hypophysectomy
breast cancer
cancer
progesterone therapy?
estrogen therapy?
tumor growth
tumor progression</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8ED8D02-7F93-41B5-908B-D5A8A907DF30">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbcb582457d94416da18b28bd7cfca1c4">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:630171C7-516F-4D9F-AFE2-922953BD73B5">
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A76CAD7-6AFA-4C1E-AFDD-B56F1FA2AD22">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>ESR1 vs ER_Receptor? Why does the FDA table refer to PGR?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A5CFBDE8-6046-48AB-B4B8-ADFE7C6BE368">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>metabolism?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D046B8D-B703-41C7-8517-71383B7A565A">
    <ncit:Alleles>VKORC1-1639G&gt;A</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2E40CE4B-F0A4-4DD0-B730-62D6531EBDAF">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:76</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>BCR/ABL1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:075A7CA2-6401-4610-A335-F1E2AE43B9E0">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:26F559B1-5DFA-4EBF-BEA5-4446B69F0CCE">
    <ncit:Alleles>CYP2C9*1, CYP2C9*2, CYP2C9*3</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CAB1083A-95FB-4729-BB49-0C452F7641BC">
    <sio:SIO_000111>(42232-9) PRECAUTIONS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(42232-9) PRECAUTIONS</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:801E4361-583C-4097-9F47-7910FDF70718">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8A08744-2AEE-46C6-95C7-7CD50737E7F4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8000C8F-8664-487A-B6F5-84E4C4319FE2">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2ADEE0A-98B3-4299-980C-3EBF27CC5983">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:23B5DEBF-032B-44AD-86B6-0A5665A87474">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F810FB25-3A57-4784-8C4E-A29CCA74AAB3">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21BD891C-1A7D-4254-B84D-F08896010FBE">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C085D6FD-C375-4444-ADF0-98B2C81E9630">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E932C75-BC6C-4269-AE1B-871FF55D1BFD">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:451D05CA-4BB1-46B3-81DE-57753077DCC2">
    <ncit:Alleles>G20210A</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA081AF8-B5DD-4E3F-8A59-4FFBAD50147B">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0085D334-E933-4121-AA4D-45C85FA79976">
    <poc:Comment>double annotation due to two genes</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA36C067-E5FD-411F-9D92-749CA81A5155">
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:753AA500-D0F4-4E93-B6AA-97DAFC61A156">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C856BE8E-DEA3-4EBC-BAE5-826826C36CF9">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>I see that you all had ESR1 but have no idea where you found that information on the label.</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F18EABFA-DE53-4697-A79C-CE2728D2CEAF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Not necessary</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-necessary</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is not necessary.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:624952BE-02FA-4DBB-A8F8-7C324A7D27AE">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>BRCA1, BRCA2 need to be added to HGNC Gene Symbol selection</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC5244F5-E70F-46C2-80A7-DA06EB1332C9">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26386F6E-0E97-4ACB-AFBA-2C331A2E54E4">
    <pav:createdOn>2014-06-01 20:37:15 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:26386F6E-0E97-4ACB-AFBA-2C331A2E54E4"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:exact>Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. Treatment of women with letrozole significantly lowers serum estrone, estradiol and estrone sulfate and has not been shown to significantly affect adrenal corticosteroid synthesis, aldosterone synthesis, or synthesis of thyroid hormones.</ao:exact>
    <domeo:uuid>26386F6E-0E97-4ACB-AFBA-2C331A2E54E4</domeo:uuid>
    <ao:prefix>endent tumors. In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum FSH. Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B77509C-B4A9-48D8-8281-20CE902E914A">
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A7FEED2-54CF-46CF-805B-6B2CBE0A39E2">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FAB26198-EF81-4447-AB54-8786FC5EDE47">
    <rdfs:label>Recommended</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FD29F999-6BE6-4296-85E2-66DAA123889B">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:02D85B22-A258-4FF9-89AB-216AC9D5DDA9">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E5439B7-EE16-4080-9092-7E25F09413EA">
    <pav:createdOn>2014-06-11 14:12:45 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>5E5439B7-EE16-4080-9092-7E25F09413EA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Table 5Range of Expected Therapeutic Warfarin Doses Based on CYP2C9 and VKORC1 Genotypes*\nVKORC1CYP2C9*Ranges are derived from multiple published clinical studies. Other clinical factors (e.g., age, race, body weight, sex, concomitant medications, and comorbidities) are generally accounted for along with genotype in the ranges expressed in the Table. VKORC11639 G(rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3 and *3/*3 may require more prolonged time (&gt;2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen.*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5 to 7 mg5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mgAG5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mgAA3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5E5439B7-EE16-4080-9092-7E25F09413EA"/>
    <ao:prefix>In all patients, subsequent dosage adjustments must be made based on the results of PT/INR determinations.17, 18 </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04514E5A-CC45-47DE-9281-2FBD57AC110F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <pav:createdOn>2014-06-02 11:50:09 -0400</pav:createdOn>
    <ao:exact>Tamoxifen and N-desmethyl tamoxifen plasma concentrations have been shown to be reduced when coadministered with rifampin or aminoglutethimide. Induction of CYP3A4-mediated metabolism is considered to be the mechanism by which these reductions occur; other CYP3A4 inducing agents have not been studied to confirm this effect.</ao:exact>
    <ao:prefix>Tamoxifen reduced letrozole plasma concentrations by 37%. The effect of tamoxifen on metabolism and excretion of other antineoplastic drugs, such as cyclophosphamide and other drugs that require mixed function oxidases for activation, is not known. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:04514E5A-CC45-47DE-9281-2FBD57AC110F"/>
    <domeo:uuid>04514E5A-CC45-47DE-9281-2FBD57AC110F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:765BDF55-5CD5-41A1-90E1-CCA6B2630B53">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34066-1) BOXED WARNING</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34066-1) BOXED WARNING</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B40CB31-3B71-4F4B-813B-2D43EBE098D9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:93985C36-8602-4407-801B-79E9A717126E">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34068-7) DOSAGE AND ADMINISTRATION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34068-7) DOSAGE AND ADMINISTRATION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:056DFCFD-7A3D-456D-BD1C-B5E0D7699D95">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:69FCE2CA-34CA-475D-998B-7830A6F1026B">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DFF63EA5-24A8-454C-ABA1-468160F5E182">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>double annoatation</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC96A550-4FD5-41F2-AFF2-8D9B4B59855E">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>respiratory depression, death, tonsillectomy, adenoidectomy, nursing infants, lactating mothers</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:05D03B82-E435-4E7C-9A43-AE9C7DF29A1F">
    <poc:MedicalCondition>Protein C deficiencies, Protein S deficiencies, tissue necrosis</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06682B01-A432-4E05-8191-6DAD4683C330">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:500DFBF4-B18A-4741-B094-607CF87944D6">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:669C65A2-428A-40D8-AB6B-42D149C8F608">
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2830055A-ACED-40B1-B6C6-27369CCE01C6">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9271B114-3F36-4AF9-8EE0-D60F5AB36CD2">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>I elected to not highlight the last sentence that refers to the contraindication. Although the contraindication is likely due to possibility of UM status, the contraindication exists regardless of the metabolizer status of the pediatric patient.  </poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F3E7263-8583-4D92-9FAC-6592640CB6F1">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:68F2DD63-C330-4CA1-BB91-2D3A45E15087">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*1502</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8613DBE-E23B-4505-97DC-D1A8904A9B30">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000004801</dailymed:pharmgxBiomarker>
    <rdfs:label>BRAF</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:68B513A5-D56D-4DF6-A372-20CB0B78A444">
    <poc:MedicalCondition>tumor</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E9B1D3D-0924-43C5-9276-ED74DEE57EF3">
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in excretion of the drug</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#excretion-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Excretion Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:742D9FCD-2D9A-468B-B1DE-2EA9C3786782">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5C948C2D-1365-4583-BD08-43BAEFE60CC2">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3A41F800-6313-4209-8FC6-6A15248F96DC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C041AF4-2D3F-44DE-9C7C-2C3E27E3C77A">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C195A24A-0326-4ED5-8DAD-5D759C334633">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*1502</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:364E48E3-9581-476A-B552-7EF20E3B5123">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>postmenopausal women
metastatic breast cancer
advanced breast cancer
breast cancer
cancer
antiestrogen therapy</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:57037122-268D-4AA1-8C43-C8CD323EDB8A">
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:10F685C2-516D-430A-8891-5F34A306C727">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E56C5CC1-71B9-4F01-89AF-DD55E656ECE6">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>dehydrogenase (DPD) deficiency</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E05A092-48FB-442A-A294-377B4591CEBA">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>liver disease, </poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B80F8EAB-7286-4F17-A56E-99B9BCB60FAC">
    <rdfs:label>Imipramine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00458</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ECF411C7-5E58-4EB7-ABF0-33EEE5C22D04">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>How many annotations
I count 3 for positive, poor, and unknown.
</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:95A76A81-86B0-46DB-A84C-D2B04F69E41B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>extreme sleepiness, confusion, shallow breathing, lactating mothers </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A46F543-9241-436B-B829-9D81FA185E51">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>double annotation</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E118AF70-C2CB-42BF-9C66-805D9273A823">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>medication guide = patient medication information?\n</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CE880A6-611C-44C6-A607-47BBCF65589F">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>double annotation</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DC9DDD0-E979-4202-B695-57DAC5E82F5D">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A83D4B39-1BC1-4311-9DC6-45C82270D3D9">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2632350-81DF-4377-8B1B-40C64610E1A3">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:159DE912-8E3E-4C8A-952C-5D56B03F4261">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:939C0307-55CE-4736-AA11-38175F4EE10A">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>ESR1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:46F6BA9D-79BA-48A7-91D5-BBFC46775697">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34070-3) CONTRAINDICATIONS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34070-3) CONTRAINDICATIONS</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E22833FF-9C8C-4AAF-BF61-7A1BAC88B9EE">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8650AFA8-B61A-4A92-A987-B371590DFBCE">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:88018830-0B5D-482E-8031-2EC6F411DB72">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F39A73F6-352B-45D8-93F4-B75B7DAE8DCA">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:66C8E7B7-9098-4C5B-9CE9-3A7593AD36C5">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:70D9843F-2457-40EE-B7FF-821A778215A9">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:661F6C14-327C-4CB7-86D0-5549D22CDEC4">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2B19285-CDA5-4F48-BD66-9F40377683C6">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CE4D16B-9B9B-4D0E-BBC4-6DC2E11BE320">
    <poc:Comment>annotated the entire section in order to include "do not take"</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B06CC265-F8E0-4C28-9939-880EF88A5101">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43682-4) PHARMACOKINETICS</poc:productLabelSection>
    <sio:SIO_000111>(43682-4) PHARMACOKINETICS</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE123E60-78DB-4994-B150-CB634849D239">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EACA5F51-F689-4BD5-9065-802E3BB0555A">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:62084687-82BB-4416-B629-C03B05181B86">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F700493-AE5A-4434-A675-08B61AB15CC6">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>CYP2C9*2, CYP2C9*3</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C59A6BE-0F50-4E5A-80AD-A6BA98CD420D">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43682-4) PHARMACOKINETICS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(43682-4) PHARMACOKINETICS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE4B0A7F-465B-4C17-852A-BF262924757C">
    <sio:SIO_000111>(68498-5) PATIENT MEDICATION INFORMATION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(68498-5) PATIENT MEDICATION INFORMATION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45F7DA71-DCBA-4667-AD78-F695417EFD56">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF4B710F-A32F-47E2-BECB-106A837F1F66">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:724D3B35-67C5-43A4-BC96-46E359B92EE8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A04E56DA-84EB-468F-A39D-5ED23FC1F1A3">
    <rdfs:label>Clomipramine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01242</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4831C32E-AE3F-431D-AFED-F707745EA4D6">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CD32F7C-E76A-467D-8B6E-40F20B070501">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2820E75B-959F-4C6A-8D67-AD9C22292B75">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>PROC?? CURRENT GENE SYMBOL IS INCORRECT </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7240E388-B7B2-4EC5-9469-402AAC33AFF4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(43685-7) WARNINGS AND PRECAUTIONS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43685-7) WARNINGS AND PRECAUTIONS</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2D29067-AA5B-46D8-9CFF-9C566C9441E9">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0245F231-BF84-4799-9D5F-88730A3415D9">
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:46515176-CB42-4873-966D-0A5D67496F43">
    <poc:MedicalCondition>respiratory depression, death, tonsillectomy, adenoidectomy</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7A499F53-8865-41FD-8795-0FA09E5EB038">
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC00101D-0828-425E-8C39-55A240DC2F1E">
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BBE9B27F-7731-4E0A-9729-BA2B9CE568DF">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6EE754B-3ACF-4D28-82B0-173F818815F2">
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5DD7301F-B239-42ED-8AC3-535CF0C77261">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>postmenopausal women
early breast cancer
breast cancer
cancer</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51D8AD88-84BD-499D-89B1-5A13D094E89B">
    <poc:Comment>BRCA1 and BRCA2 are not found in the FDA table. Are they relevant? Would this statement be annotated if they were? ESR1 was used as a place holder for the required section.  </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CDAA9AA2-EF56-4941-8EA2-F8E33BC70076">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>The sentences following the annotation do not directly deal with the genetic information</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:420A7745-DFE2-4507-BB59-E65C8E96F633">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EBD286B2-69F4-4FD8-B7B2-6FED02812F9B">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52BAA8DA-2ECD-484F-A401-FC81FB13BC72">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>lactating mothers, death, nursing babies</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB722835-42BD-4854-8617-167FC619CE9D">
    <sio:SIO_000111>68498-5 PATIENT MEDICATION INFORMATION SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#68498-5 PATIENT MEDICATION INFORMATION SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:479A731B-392C-41AA-8F76-401D07ECF42F">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>this obvisisouly important information, but I believe it suppose to be a tablet? multiple annotations could be made here.</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C2415F89-08E6-49E1-8F21-8500F57364A5">
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB7F5CE5-2A4D-469D-82B4-26C64B9D23AD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:83CD3AC9-0F79-45ED-B263-CC7B66B0454D">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA139D1F-5943-42B5-B46F-936534FF180D">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>BRCA1 BRCA2</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4FDB6D9-6003-4748-9F44-DAD96C90C75E">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4693793C-A4BA-4B78-8FEF-0E9B1A3DCA6D">
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8AB3F2D0-8322-4A48-B07A-0D5ECB04CB02">
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AB147F25-1B88-4069-9256-A953968F81BF">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5F0D7FB-E816-4314-B450-214BD51BDA11">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:46FF888B-BFA9-44D7-9252-A859CD65C03E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>lactating mothers, breastfeeding infants, death</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0E35AA6-356F-4054-945A-07801C6240FC">
    <poc:Comment>HGNC gene symbol confusion as to which</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbcc8ead230b2468bb617a5832941fc6f">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8f6d72116c5b4af79c00733275d1f264">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F15080E5-46CA-41ED-8B36-0985F56D56BF">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6D861CA-F528-4F4C-9D8C-092E0C266BCA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A49AA2B-31C9-4E3C-9873-E0CF6F23B89A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>metabolism? </poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4D2018B-33A0-45F5-87FC-D51E7B320CD3">
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0388B3EC-40C4-447D-9172-3E925C19BB6A">
    <poc:Comment>double annotation</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
</rdf:RDF>
